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Prepubertal boys treated for cancer may exhibit impaired fertility in later life. A
number of chemotherapeutic agents have been identified as being gonadotoxic, and
certain treatment regimens, such as that used for Hodgkin's disease, are particularly
associated with subsequent infertility. Radiotherapy may also cause gonadal damage,
most notably following direct testicular irradiation or total body irradiation.
Semen cryopreservation is currently the only method of preserving fertility in patients
receiving gonadotoxic therapy. This is only applicable to postpubertal patients and
can be problematic in the adolescent age group. At present there is no provision for
the prepubertal boy, although there are a number of experimental methods currently
being investigated. By harvesting testicular tissue prior to gonadotoxic therapy,
restoration of fertility could be achieved following treatment, either by germ cell
transplantation or by in vitro maturation of the germ cells harvested. An alternative,
and potentially more acceptable method of fertility protection is to render the testes
quiescent during cytotoxic treatment, thereby reducing the susceptibility ofgerm cells
to subsequent damage.
However, attempts to protect gonadal function by suppression of the reproductive axis
in primates have been unsuccessful, possibly because spermatogonial proliferation
may be gonadotrophin independent. The primary aim of this project, using the
marmoset monkey as an animal model, was to investigate whether spermatogonial
v
proliferation in this species is independent of gonadotrophins. Secondly, if this were
to be confirmed, the aim was to identify factors that do regulate their proliferation, as
a step towards devising strategies for fertility preservation in boys treated for cancer.
Methodology and Results
Immunohistochemistry was used on Bouins-fixed marmoset testes from birth to
adulthood, including tissue from males treated prepubertally for ten weeks with a
GnRH antagonist, to elucidate the role of gonadotrophins. No difference was found
between germ cells from control and GNRH antagonist-treated animals in the
immunoexpression ofMAGE, a germ cell-specific marker, Ki67, a marker of cell
proliferation, and Histone H3, a marker of cell mitosis, confirming that
spermatogonial proliferation is gonadotrophin-independent.
To determine potential regulators, spermatogonial immunoexpression ofgrowth
factor receptors was investigated. Receptors for several growth factors were identified
in spermatogonia. The expression of receptors for both Epidermal Growth Factor and
Neurturin was pronounced in a proportion ofgerm cells in late infancy, thus
implicating a role for these factors in spermatogonial development. Prepubertal
expression of these receptors was unaffected by prior treatment with a GnRH
antagonist, demonstrating their gonadotrophin independence. Studies using confocal
microscopy demonstrated that the spermatogonial population expressing these
receptors were not actively proliferating, raising the possibility that these factors act
to inhibit proliferation. Manipulation of these factors may protect fertility in boys
treated for cancer.
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As survival of stem spermatogonia is essential for future fertility, this study also
attempted to identify a marker of stem cells in the primate, in order to investigate their
activity prepubertally. GFR-al, the receptor for Glial Cell Line-Derived
Neurotrophic Factor, is expressed by A-spermatogonia in the mouse. In marmoset
testis, expression of this receptor was shown in occasional germ cells, in a pattern
consistent with stem cells, at all ages studied. Attempts to co-localise GFR-al with
cell cycle markers suggest these cells are not actively proliferating, but further studies
are underway to fully investigate these cells, and their relationship with the growth
factors already identified in this primate model.
Conclusions
These results confirm that spermatogonial proliferation in the prepubertal primate
testis is gonadotrophin independent. These studies have also identified growth factor
receptors expressed by spermatogonia during infancy, and have demonstrated that
these are not regulated by gonadotrophins. In addition, a potential stem cell marker
has been identified in the primate testis. Further investigation of these growth factors,
and their relationship with stem cells within the testis, will contribute to the
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Chapter 1
Introduction- Male Fertility following Childhood Cancer
1.1 Introduction
Survival from childhood cancer has markedly improved over the past few decades
following major advances in available treatments and supportive care, such that now
around 75-80% of children with cancer will be alive five years from diagnosis (Mertens
et al, 2001). The number of long term survivors is therefore increasing, and it has been
estimated that by the year 2010, about one in 715 of the adult population will have been
treated for cancer in childhood (SIGN Guideline 76, 2004).
Because of this, the emphasis in the management of childhood cancer has changed from
"cure at any cost" to one in which quality of life both during and after treatment has
become increasingly important. Thus whilst continuing to strive for improved survival,
attention must also be directed towards minimising the late effects of treatment.
Adverse late effects of childhood cancer treatment are diverse and include disorders of
the endocrine system, cardiac and pulmonaiy dysfunction, renal and hepatic impairment,
secondary malignancies and psychosocial difficulties.
Although problems with fertility do not become apparent until after puberty, it is clear
that many treatments for childhood cancer can lead to infertility and sub-fertility in later
life (Waring and Wallace, 2000). This can have a particularly devastating impact as the
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patient enters adulthood. Having survived cancer as a child it can be very difficult for
many such patients to accept that they cannot produce their own children because of the
treatment they received earlier in their life. It is therefore imperative to consider, at an
early stage, strategies that may protect or restore fertility in later life.
This chapter will discuss the aetiology of reduced fertility following treatment for
childhood cancer in the male, and the ability to predict future fertility potential after
particular treatment regimens. At present the options available to protect or restore
fertility in this patient group are limited. However, there are a number of novel
experimental strategies, which are currently generating much interest within the scientific
community. The potential benefits and disadvantages of these strategies are outlined,
before a more detailed discussion ofone option, 'hormonal manipulation', which forms
the basis of the work described in this thesis.
1.2 Anatomy and Physiology of the Testis
In order to appreciate the basis ofmale subfertility, both secondary to cancer treatment
and from other causes, it is essential to understand testicular function. The adult testis
fulfils two essential roles, the production and maturation ofmale gametes
(spermatogenesis) and the synthesis and secretion of testosterone (steroidogenesis).
Although the prepubertal testis does not complete these processes it is vulnerable to
cytotoxic damage, and therefore testicular development during this period must be critical
for normal function following puberty.
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Spermatogenesis and steroidogenesis occur in two compartments of the testis which,
although morphologically distinct, are functionally inter-related.
Testosterone is produced and secreted by the Leydig cells, located within the interstitial
compartment. This testosterone both diffuses into the nearby seminiferous tubules, and
enters the systemic circulation for distribution to its numerous target organs. In addition
to Leydig cells, the interstitial area also contains macrophages, lymphocytes, blood and
lymph vessels and connective tissue.
Spermatogenesis occurs within the seminiferous tubules. This compartment represents
approximately 60-80% of the total adult testicular volume and, overall, the human testis
contains about 600 seminiferous tubules. The wall of each tubule is composed of
peritubular myoid cells that contract to cause peristalsis of the tubule (Maekawa et al,
1996), required for the transport of fully formed spermatozoa. Each end of the tubules is
connected to the rete testis, which in turn connects to the epididymis via the efferent
ductules (Fig 1.1). The seminiferous tubule contains two cell types, Sertoli cells and
germ cells. The inter-relationship of these cell types within the epithelium of the tubules
is essential for normal spermatogenesis, and will therefore be discussed in more detail.
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Figure 1.1 Basic Anatomy of the Testis
Illustration of the anatomy of the testis, rete testis, efferent ducts, the regions of the
epididymis and the vas deferens and their proximity to each other.
, EPIDIDYMISInitial
Adapted from Robaire and Hermo (1988)
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1.2.1 Sertoli Cells
Sertoli cells are somatic cells, and are responsible for nurturing the developing germ
cells, from stem spermatogonia through to mature spermatozoa. They are located on the
basement membrane, but their prominent cytoplasmic projections extend to the lumen of
the tubule (Fig 1.2). This enables Sertoli cells to remain in both morphological and
functional contact with the germ cells and, as demonstrated in Fig 1.2, these germ cells
will be at different stages ofdevelopment. Each Sertoli cell can only support a finite
number ofgerm cells (Russell and Peterson, 1984), and therefore the number ofSertoli
cells per testis will be an important factor in determining the number of sperm able to be
produced.
Neighbouring Sertoli cells form inter-connecting tight junctions, which form the basis of
the 'blood-testis barrier'. The diploid spermatogonia are located outside of this barrier in
the 'basal compartment', whereas all meiotic and post-meiotic germ cells reside within
the 'adluminal compartment', which is behind this barrier (Fig 1.2). It is thought that this
barrier protects these haploid germ cells from immune recognition. However, because
germ cells in this adluminal compartment are isolated, they do not have direct access to
nutrients and hormones. They are therefore dependent on Sertoli cells for these
requirements. In order to fulfil this role, Sertoli cells produce and secrete tubular fluid,
which creates and maintains the patency of the tubular lumen (Griswold and Russell,
1999). This unique fluid immerses the germ cells, and presumably aids meiosis and
sperm development. In addition to this fluid, Sertoli cells synthesise and secrete a large
variety of factors including cytokines, growth factors and prostaglandins, which are likely
5
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to act on the germ cells in a paracrine manner. Sertoli cells not only support developing
germ cells, but are also responsible for phagocytosis ofdegenerating germ cells. In the
human testis, as many as one third ofgerm cells degenerate by apoptosis (Johnson et al,
1984).
1.2,2 Germ Cells
Within the epithelium of the seminiferous tubule, germ cells mature from stem
spermatogonia into spermatozoa capable of fertilisation. This maturational process,
termed spermatogenesis, consists of three broad phases. Firstly, diploid spermatogonia
undergo mitotic proliferation and differentiation to produce spermatocytes. Secondly,
meiotic division of these spermatocytes results in the formation of haploid spermatids.
Finally, these haploid germ cells transform into mature spermatozoa, predominantly via
nuclear condensation with loss of cytoplasm and the formation of a flagellum. This final
phase is termed spermiogenesis (Fig 1.3).
Spermatogonia are situated on the basement membrane of the seminiferous tubule, and
are classified into two types, type A and type B. A-spermatogonia are further subdivided
into Ad (dark) and Ap (pale), based on their cytological appearance following staining
with haematoxylin (Clermont, 1966). Ad spermatogonia can be considered as 'reserve'
stem cells. They are not proliferative under normal circumstances, but do become active
when the number ofAp spermatogonia is reduced, for example after irradiation (van
Alphen and de Rooij, 1986). In contrast, Ap spermatogonia divide once every epithelial
cycle to produce B-spermatogonia (Sharpe, 1994). Mitotic division ofB-spermatogonia
7




























gives rise to daughter cells that enter meiosis as preleptotene spermatocytes. These
spermatocytes develop through leptotene, zygotene and pachytene phases to produce
secondary spermatocytes. The final meiotic division of the latter cells subsequently
produces four haploid round spermatids. These spermatids then undergo spermiogenesis
to form mature sperm, which are released into the tubule lumen.
1.2,3 Organisation ofSpermatogenesis
The progression ofgerm cells through this maturation process is ordered both in time and
in space. As mentioned previously, Sertoli cells are in contact with a number ofgerm
cells at different steps of this process. However, the different types ofgerm cell
associated with one particular Sertoli cell is not random but is highly co-ordinated, in that
cells at certain steps ofmaturation are only ever associated with cells at certain other
steps. In this manner, spermatogenesis can be divided into certain stages, as
demonstrated in Fig 1.4. Each stage represents the associations ofgerm cells at particular
steps in the maturation process. When a germ cell completes the final stage at one level it
subsequently progresses to stage I again, but at the next level, which becomes
progressively more luminal. In this way each germ cell passes through the stages several
times, before maturation into a spermatozoon.
Because Sertoli cells are in contact with germ cells at different steps ofdevelopment, and
those germ cells present are specific for particular stages ofspermatogenesis, the function
of Sertoli cells will change dependent on that particular stage. In other words, as germ
cells progress through spermatogenesis, their requirements from the Sertoli cell will
9
Figure 1.4 Germ Cell Associations at the Different Stages of the Soermatogenic
Cycle in the rat (left) and in man (right) (from Sharpe, 1994)
Rat Man
I II III IV V VI VII VIII IX X XI XII XIII XIV I II III IV -v VI
Stages of the cycle _
34.8 23.3 6.0 13.0 14.7 26.5 62.8 21.3 7.1 7.1 7.1 32.3 17.6 14.1 93.0 043 52.4 48.0 86.4 26 4
Duration in hours
Y/A Spermatogonia! I 1 , \/ J i\\\\j Nudea/ condensation / FwTi Cytoplasmic eliminationDZJ freolicative} phase I 1 Meo"c phaM Acrosomal phas« tlwgationphaM fa! and feleas8 phaM
Each vertical column or stage describes the fixed complement ofgerm cells associated
with Sertoli cells at that particular stage, with the lumen at the top and the basement
membrane to the bottom of the diagram. Each stage lasts a fixed period of time
(indicated along the bottom), at the end ofwhich each germ cell type within that stage
will have developed into a germ cell characteristic of the following stage. The complete
process of spermatogenesis can be divided into phases based on developmental events
that occur. Thus there is an initial spermatogonial phase (A in rat, Ad and Ap in man)
(arrowheads show when sequential mitoses occur), following which the B-spermatogonia
(B) enter the meiotic phase as preleptotene spermatocytes (PI) and subsequently develop
through leptotene (L), zygotene (Z) and pachytene (P) primary spermatocyte stages
before the final meiotic division (II, secondary spermatocyte), during which each
spermatocyte gives rise to four haploid round spermatids. These then enter
spermiogenesis, encompassing acrosome development, nuclear condensation, elongation
and finally release of the spermatid, which on release is termed a spermatozoon.
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change accordingly. These cyclical changes in Sertoli cell function appear to be largely
modulated by the germ cells themselves, with the particular complement ofgerm cells
associated with the Sertoli cell determining its function (Parvinen, 1993).
The number ofmorphologically identifiable stages of the spermatogenic cycle differs
depending on the species. The cycle in rats is classified into XIV stages, whereas in
humans only VI can be distinguished. Each stage lasts a fixed period of time, and
progression from stages I to VI lasts around 13V2 days in the human. Because each
human germ cell passes through these stages 5V2 times, the overall duration of
spermatogenesis lasts around 74-76 days (Sharpe, 1994).
The arrangement of these stages within the seminiferous tubule is also organised in a
particular manner. In the rat, and indeed the majority ofmammalian species, these stages
have a 'segmental' arrangement along the tubule (Fig 1.5). Microscopic examination of a
cross-section of such a tubule will demonstrate the presence ofonly one stage and,
consequently, only the germ cell types present within that stage will be evident. In
contrast, examination of the cross-section ofa seminiferous tubule from the human
demonstrates the presence of a number of stages within the same cross-section (Fig 1.5).
Although this appearance initially suggests these stages are arranged randomly, more
detailed examination suggests that there is a 'helical' arrangement ofthe different stages
along the length of the tubule (Schulze et al, 1986). The great apes also exhibit a
'helical' arrangement of stages, but the majority of primates used widely for research,
such as the rhesus monkey, exhibit a 'segmental' pattern (Sharpe, 1994). In contrast, the
11
Figure 1.5 The Arrangement of the Stages of Spermatogenesis along the
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marmoset exhibits a pattern that is somewhat intermediate between 'segmental' and
'helical', though is generally quite similar to the human (Miller et al, 2000).
Because a number ofdifferent stages of spermatogenesis are present within a cross-
section of a tubule from animals with a helical arrangement, interpretation of these
tubules under a microscope can be more problematic than examination of rodent testes.
More importantly, animals with a segmental arrangement are associated with highly
efficient spermatogenesis. In contrast humans, and other animals known to exhibit a
helical arrangement of spermatogenesis, are recognised as inefficient. It is uncertain
whether this latter arrangement causes the inefficiency, or alternatively that inefficient
spermatogenesis leads to the development of a helical pattern (Schulze and Salzbrunn,
1992). However, this highlights an important difference between spermatogenesis in
rodents as compared to humans and certain other primates, and illustrates that there are
limitations in extrapolating data regarding spermatogenesis between these species.
1.2,4 The Regulation ofSpermatogenesis
The hypothalamic-pituitary-gonadal axis has an essential role in regulating
spermatogenesis in the post-pubertal testis. However, given that post-meiotic germ cells
are isolated from circulating hormones by virtue of the blood-testis barrier, the main
aspects of this control are indirect, predominantly via Sertoli cells. Thus a combination
of endocrine, paracrine and perhaps autocrine factors are likely to be involved.
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1.2.4.1 Hormonal Control of Spermatogenesis
For normal spermatogenesis to occur, the testis requires stimulation by the pituitary
gonadotrophins, the secretion ofwhich is regulated by gonadotrophin-releasing hormone
(GnRH) from the hypothalamus. Follicle Stimulating Hormone (FSH) acts directly on
the seminiferous epithelium, whereas Luteinizing Hormone (LH) exerts its influence on
spermatogenesis by stimulating testosterone secretion from the Leydig cells. Both
gonadotrophins are under negative feedback control, with testosterone inhibiting their
secretion. In addition inhibin B, produced by the Sertoli cell, is involved in the negative
feedback control ofFSH (Anderson and Sharpe, 2000).
Matsumoto and Bremner (1989) induced gonadotrophin deficiency in normal men by the
administration of testosterone at high doses, resulting in oligospermia or azoospermia.
Sperm counts increased on selective replacement of either LH activity or FSH activity,
but remained below those within the control group. Thus normal levels ofboth FSH and
LH are required to achieve quantitatively normal sperm production in man.
Although both FSH and testosterone appear to be essential for normal spermatogenesis,
the precise role ofboth these hormones in the testis is uncertain. Germ cells do not
possess receptors for either FSH or testosterone. However, Sertoli cells express receptors
for both hormones, and androgen receptors are also present on peritubular cells (Bremner
et al, 1994). These cells therefore act as intermediaries, with FSH and testosterone acting
on germ cells in an indirect manner.
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Testosterone is essential for the maintenance of normal spermatogenesis in the post-
pubertal testis. This hormone acts in both an endocrine and paracrine manner, as not only
circulating levels must be adequate, but also intratesticular transport of testosterone is
essential for complete spermatogenesis in mice (Takaimiya etal, 1998). Indeed,
intratesticular levels of testosterone must be sufficient for normal spermatogenesis to
occur in both rodents and primates (Sharpe, 1994). In addition, testosterone also has a
role in spermiogenesis and spermiation (McLachlan et al, 2002).
As explained previously, androgen receptors are not present on germ cells, and therefore
testosterone presumably acts via the Sertoli cell, and perhaps the peritubular cell.
Withdrawal of testosterone in the rat results in germ cell degeneration, but only at certain
stages of the spermatogenic cycle (Dym and Raj, 1977; Sharpe, 1994). Thus testosterone
may act only upon certain stages of spermatogenesis, rather than having a more general
effect (Sharpe, 1994). This stage-dependent regulation reflects the intimate coupling of
Sertoli cell function and germ cell maturation.
The role ofFSH in adult spermatogenesis is difficult to elucidate, in part because of
apparent differences between rodent models and primates. Immunoneutralization of
endogenous FSH has little or no impact on spermatogenesis in rats (Davies et al, 1979),
whereas in non-human primates it can lead to a significant suppression of
spermatogenesis and sperm output (Wickings and Nieschlag, 1980). Indeed, FSH has
been shown to play a role in the progression of type A to type B spermatogonia in
primates (McLachlan et al, 2002). In contrast, regulation of spermatogonia! replication
15
and differentiation in rodents is not mediated primarily by FSH, but more by density-
dependent regulatory factors (Sharpe, 1994). This relates to the higher number of
spermatogonial cell divisions exhibited by the rodent, resulting in the number ofB-
spermatogonia entering meiosis being maintained at maximal levels. In primates the
number ofB-spermatogonia is well below these levels. This further highlights significant
differences between spermatogenesis in rodents and in certain primates, particularly with
regard to overall efficiency.
Although FSH on its own may not appear as significant as testosterone in the regulation
of spermatogenesis, especially in rodents, it does exhibit synergistic action with
testosterone, particularly with regard to the regulation of germ cell viability (McLachlan
et al, 2002). FSH increases the availability ofgerm cells at certain steps ofdevelopment
for entry into the androgen dependent phases of the spermatogenic cycle (Sharpe, 1994).
As with testosterone, these FSH-mediated effects are likely to be via the Sertoli cell, as
germ cells do not possess FSH receptors. Thus interaction between the Sertoli cell and
germ cells is vital and, as mentioned previously, the changing germ cell complement
from stage to stage determines the alterations in hormonal responsiveness of the Sertoli
cell (Parvinen, 1993).
1.2,4.2 Local Control ofSpermatogenesis
Whilst spermatogenesis is regulated in part by systemic factors, in particular FSH, it is
clear from the above discussion that regulation also exists within the testis at a local level.
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Factors produced locally are likely to be important in the modulation of hormonal
activity, particularly at different stages of the spermatogenic cycle.
Firstly, testosterone, produced by the Leydig cell, has important actions locally in the
seminiferous tubules. As discussed above, an adequate level of intratesticular
testosterone is essential for the maintenance ofnormal spermatogenesis.
Secondly, as mentioned previously, each Sertoli cell can only support a fixed number of
germ cells to maturity, and therefore the number of Sertoli cells present will determine
the level ofpotential sperm output. In the rat, FSH is the most important regulator of
Sertoli cell replication (van den Dungen etal, 1990), and this ceases during neonatal life
with Sertoli cell maturation and the formation of tight junctions between adjacent Sertoli
cells (Sharpe et al, 2003a). A similar situation exists in man, although a degree ofSertoli
cell replication may continue throughout the prepubertal period (Cortes etal, 1987;
Sharpe et al, 2003a).
It is clear that both FSH and testosterone have essential roles in spermatogenesis.
However, an increasing number ofgrowth factors and cytokines have been identified
within the testis, and these are also likely to be important with regards to testicular
function. The main emphasis of this project is the identification of these factors in the
primate testis, and as such will be discussed in more detail later on.
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1.2.5 Testicular Development
Whilst much of the preceding discussion relates to the adult testis, the patient group
around which this project focuses is prepubertal. It is therefore appropriate to discuss
development of the testis, and the functional changes that occur through foetal, neonatal
and prepubertal phases ofmaturation.
1.2,5.1 Foetal and Neonatal Development
The testis exhibits a number ofcritical phases of development during foetal and neonatal
life. As there is considerable overlap in the timing of these phases, both periods will be
considered together.
The embryonic testes develop from the indifferent gonads, which are mesoderm-derived
structures located either side of the dorsal aorta and neural tube. Differentiation into
male gonads occurs at around 7 weeks of foetal life in the human, directed by the
expression of the testis-determining SRY gene on the Y chromosome (Gubbay etal,
1990).
The indifferent gonad consists of four major cell types, reflecting those cells present in
the mature testis. Firstly, the supporting cell lineage gives rise to Sertoli cells in males.
As discussed previously, proliferation of these cells in both foetal and neonatal life is an
important determinant of future sperm production. Although FSH is important in the
postnatal regulation of Sertoli cell replication, it has been demonstrated using murine
models that foetal development of Sertoli cells is independent ofgonadotrophins (Baker
18
and O'Shaughnessy, 2001), and may instead be androgen-dependent (Johnston etal,
2004).
Secondly, cells from the steroidogenic lineage are the precursors ofLeydig cells. During
normal testicular development, two separate populations ofLeydig cells arise in a
sequential manner. The 'foetal population' is present soon after testicular differentiation,
and these cells produce testosterone, required for masculinization of the male foetus. In
humans, unlike rodents, this population exhibits a further wave ofactivity causing a
testosterone peak in the neonatal period, the role ofwhich remains uncertain (Mann and
Fraser, 1996). The 'adult population' of Leydig cells develop later, and are responsible
for masculinization at puberty, and its maintenance throughout adulthood (Saez, 1994).
Thirdly, the connective cell lineage gives rise to the peritubular myoid cells in the male.
These cells migrate from the mesonephros into the developing gonad (Brennan and
Capel, 2004).
The fourth important cell type present is the germ cells themselves, and these begin as
Primordial Germ Cells, located in the endoderm of the yolk sac. These cells migrate into
the gonad by the 6th week of foetal life and become surrounded by Sertoli cells (Brennan
and Capel, 2004). Subsequently these germ cells, now known as gonocytes, migrate
towards the basement membrane of the primitive seminiferous tubule. Pseudopod
development, required for this migration, is dependent on the presence of c-kit, the
receptor for Stem Cell Factor, which is expressed by gonocytes during the foetal and
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neonatal period (Orth et al, 1997). Other factors are also likely to play a role in this
migration, including cell adhesion molecules, such as N-CAM (Orth etal, 1995). It
should be emphasised, however, that these findings are based solely on rodent models,
rather than primate species. Gonocytes are able to reach the basement membrane because
tight junctions between adjacent Sertoli cells are not fully formed at this stage. Having
reached this site germ cells are known as spermatogonia, and will include a subset of
cells that will provide the stem cells for future spermatogenesis.
l ,2. 5 .2 The Prepubgmj. Phase ofTesticular .Development
It is apparent that the foetal and neonatal periods of testicular development are critical for
normal function, and that the adult testis is a highly active organ responsible for
spermatogenesis and testosterone production. In contrast, the prepubertal testis has
traditionally been thought ofas a quiescent organ, with little or no significant cellular
activity.
Chemotherapy and radiotherapy target rapidly dividing cells and therefore, if the
prepubertal testis is quiescent, this organ should not be susceptible to such cytotoxic
damage. However, it is clear that cancer treatment given to prepubertal boys can impair
future fertility (Whitehead et al, 1982; Relander et al, 2000), indicating that the testis is
susceptible to such damage in this age group.
The majority of studies investigating testicular function are based on rodent models, and
because the prepubertal phase of development is relatively short in these species,
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knowledge regarding this period has been limited. However, with the use ofprimate
models, there is increasing evidence that far from being a quiescent organ, the
prepubertal testis demonstrates significant cellular activity. This activity includes a
steady turnover ofearly germ cells, which undergo spontaneous degeneration before the
haploid stage (Rey et al, 1993). In addition, as mentioned previously, Sertoli cells
continue to proliferate during this phase of development. It is postulated that this activity
is essential for normal adult function (Chemes, 2001), and therefore disruption of these
processes may affect fertility as an adult.
Therefore, if this activity also occurs in the prepubertal human testis, cytotoxic treatment
received during this time could affect gonadal function, and this might explain the effects
on fertility observed in adulthood. This project focuses on the investigation of
prepubertal testicular activity, and as such will be discussed throughout this work.
1.3 Gonadal Toxicity following cancer treatment
Gonadal damage in boys treated for cancer can result from either systemic chemotherapy
or radiotherapy involving the spinal or pelvic area. This damage may involve both the
somatic cells of the testis, the Sertoli and Leydig cells, as well as the germ cells.
Because cytotoxic treatment, by its nature, targets rapidly dividing cells it is not
surprising that spermatogenesis can be impaired after treatment for cancer. The exact
mechanism of this damage is uncertain but appears to involve depletion of the
proliferating germ cell pool, by killing cells not only at the stage ofdifferentiating
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spermatogonia (Meistrich et al, 1982) but also stem cells themselves (Bucci and
Meistrich, 1987). In addition, stem spermatogonia that do survive fail to differentiate
further (Kangasniemi etal, 1996). Although the prepubertal testis does not complete
spermatogenesis and produce mature spermatozoa, as discussed previously the testis does
demonstrate significant cellular activity at this age. Thus the timing of the gonadotoxic
insult in relation to puberty is of less importance than the nature ofthe insult itself.
1.3.1 The Effects ofChemotherapy
The nature and extent of damage to the testis from cytotoxic chemotherapy is dependent
upon the agent administered, the dose received and the age of the patient (Watson et al,
1985; Wallace etal, 1989; Wallace etal, 1991; Mackie etal, 1996). Since nitrogen
mustard was first linked to azoospermia by Spitz in 1948 (Spitz, 1948), a number of
chemotherapeutic agents have been identified as causing long-lasting or permanent
gonadotoxicity. These include the alkylating agents such as chlorambucil,
cyclophosphamide and melphalan, anti-metabolites such as cytarabine, and others
including procarbazine and cis-platin. Examples of gonadotoxic chemotherapy agents
used in recent years are listed in table 1.1, although it is emphasised that this is not
intended as a comprehensive list. However, it is important to note that not all
chemotherapeutic agents are associated with subsequent gonadal dysfunction. In
addition, most of these agents are given as part of multi-agent treatment regimens, and
thus the relative contribution of each individual drug can be difficult to determine.
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Within the testes, the seminiferous epithelium is the area most sensitive to the detrimental
effects of chemotherapy. Therefore, after receiving gonadotoxic agents, patients may be
rendered oligospermic or azoospermic but testosterone production by the Leydig cell is
usually unaffected, and thus secondary sexual characteristics develop normally (Kreuser
et al, 1987; Thomson etal, 2002a). Following higher, cumulative doses ofgonadotoxic
chemotherapy, Leydig cell dysfunction may also become apparent (Gerl etal, 2001).
The impact ofchemotherapy on testicular function has been extensively studied in
patients treated for Hodgkin's disease. Treatment of this lymphoma has involved the use
of procarbazine and alkylating agents such as chlorambucil, mustine and
cyclophosphamide. Whilst this treatment leads to excellent survival rates, the majority of
male patients have subsequently developed permanent azoospermia (Kreuser etal, 1987).
Mackie et al (1996) studied children who had received treatment with 'ChlVPP', a
chemotherapy regimen containing chlorambucil and procarbazine. The mean age at
diagnosis of the male patients investigated was 12 .2 years, and ofthese 89%
subsequently had evidence of severe damage to the seminiferous epithelium up to ten
years following therapy. This study demonstrates both the gonadotoxicity of these
agents, and also the susceptibility of the prepubertal testis. Whitehead etal (1982)
similarly followed up children treated with 'MOPP' chemotherapy, a regimen containing
mustine and procarbazine, and also demonstrated subsequent long-term testicular damage
in the majority ofmale patients. In view of these studies, treatment for Hodgkin's
disease has been modified in an attempt to reduce the gonadotoxicity, whilst maintaining
long-term survival (Thomson and Wallace, 2002).
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One such modification is a reduction in the dose of procarbazine and alkylating agents,
and the addition ofanthracycline agents such as adriamycin which, although potentially
cardiotoxic, do not permanently affect spermatogenesis. This hybrid regimen, known as
ChlVPP/EVA and consisting ofseven different chemotherapeutic agents, has been
compared to a standard regimen similar to 'MOPP' (Clark etal, 1995). However, this
hybrid regimen was found to be equally gonadotoxic, with azoospermia resulting in 95%
ofmen following treatment.
Gonadal damage may be lessened by removing alkylating agents and procarbazine
altogether, such as with the 'ABVD' regimen (adriamycin, bleomycin, vinblastine and
dacarbazine). This protocol is significantly less gonadotoxic than 'MOPP'
chemotherapy, as demonstrated by Viviani et al (1985). In this study cohort, treatment
with 'ABVD' resulted in temporary azoospermia in 33% ofpatients and oligospermia in
21%, with recovery ofspermatogenesis observed in all patients after 18 months. In
contrast, 97% ofpatients were azoospermic following 'MOPP' chemotherapy, and in the
majority this damage was permanent.
In the United Kingdom at present, treatment ofHodgkin's disease involves combination
chemotherapy, with courses ofchemotherapy that alternate between those containing
alkylating agents with those containing anthracyclines. Currently this involves 'OEPA'
(vincristine, etoposide, prednisolone and adriamycin) alternated with the potentially
gonadotoxic 'COPP' (cyclophosphamide, vincristine, procarbazine and prednisolone).
Although this exposes the child to a wide variety of drugs it is hoped that excellent
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survival rates will be obtained with minimal long-term adverse effects. Indeed, this type
of regimen for Hodgkin's disease results in significantly less gonadotoxicity than does
therapy based on alkylating agents and procarbazine alone (Anselmo et al, 1990; Longo
et al, 1997), with approximately halfofall male patients preserving their fertility.
However, treatment will continue to be modified in order to optimise the long-term future
for children with Hodgkin's disease.
1.3.2 The Effects ofRadiotherapy
The gonads are sensitive to radiotherapy, and the subsequent damage depends on the field
of treatment, total dose and fractionation schedule (Speiser et al, 1973; Rowley etal,
1974; Clifton and Bremner, 1983; Centola etal, 1994). Fractionation usually improves
the therapeutic margin, but there is evidence to suggest that the gonads are an exception
(Ash, 1980), and that fractionation may actually be more harmful to testicular function.
It has been demonstrated that doses as low as 0.1-1.2Gy can have detectable effects on
spermatogenesis in adult men (Clifton and Bremner, 1983; Centola et al, 1994), with
doses over 4Gy causing a more permanent detrimental effect (Speiser etal, 1973; Centola
et al, 1994). As with chemotherapy, somatic cells are more resistant to radiation induced
damage than are germ cells. Indeed, Leydig cell dysfunction is not observed until doses
of around 20Gy are administered to the prepubertal boy, and up to 30Gy in sexually
mature males (Shaletera/, 1989; Castillo etal, 1990). Testosterone production is
therefore relatively preserved below these doses, and thus many patients will develop
normal secondary sexual characteristics, despite severe impairment of spermatogenesis.
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Within paediatric oncology, radiation induced gonadal damage is most often encountered
following direct testicular irradiation, as used for management of testicular relapse of
leukaemia, or following total body irradiation (TBI) given prior to bone marrow
transplantation (BMT).
Radiation doses of24Gy are usually used to treat testicular involvement in leukaemia,
and this results in permanent azoospermia (Castillo etal, 1990). The effects ofTBI on
gonadal function can be difficult to elucidate as this is usually given with other treatment
modalities, including high dose chemotherapy. However, doses of9-10Gy have been
associated with subsequent gonadal failure (Leiper etal, 1987), and gonadal damage is
certainly more likely than in patients treated with chemotherapy alone (Liesner etal,
1994).
Tumours of the central nervous system are the commonest solid malignancy seen in the
paediatric population. Cranial irradiation is frequently used as a therapeutic modality in
these children. Whilst not harming the gonads directly, fertility can be affected by
disruption to the hypothalamic-pituitary-gonadal axis. Indeed, patients receiving
radiation doses of35-45Gy have demonstrated subsequent deficiencies in FSH and LH
secretion (Littley etal, 1989). The clinical sequelae of gonadotrophin deficiency exhibit
a broad spectrum of severity, from subclinical abnormalities detectable only by GnRH
testing, to a significant reduction in circulating sex hormone levels and delayed puberty.
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It has been demonstrated, at least in female patients, that the aetiology of hypogonadism
following cranial irradiation is hypothalamic GnRH deficiency (Hall et al, 1994). Thus
exogenous GnRH can be used as replacement therapy in order to restore gonadal function
and fertility.
1.3.3 The Effects ofDisease
Although many aspects of cancer treatment may affect fertility, it is important to note that
the disease itselfmay contribute to male gonadal dysfunction. Indeed, it has been
demonstrated that up to 70% ofpatients with Hodgkin's disease assessed prior to
commencing treatment have impaired semen quality (Rueffer et al, 2001). This has also
been shown with other malignancies (Hallak et al, 2000), although perhaps not to the
same extent (Botchan et al, 1997). In addition to the disease itself, other non-specific
conditions commonly observed at presentation, such as fever, anorexia and pain, can
impair semen quality (Agarwal etal, 1996). These findings on semen quality prior to
treatment have only been investigated in adult patients, as similar studies on pre-pubertal
boys cannot be performed. However, the results may have implications when options for
preserving fertility in this patient group become technically and clinically feasible.
1,4 The Potential for Fertility following Cancer Treatment
Because of the varied nature ofthe gonadal insult following chemotherapy or
radiotherapy, it can often be difficult to predict whether a child undergoing cancer
treatment will subsequently have impaired fertility as an adult. The risk of subfertility
can be categorised according to the type ofmalignancy and associated treatment (Table
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Table 1.2: Best assessment of risk ofsubfertilitv following current treatment for
childhood cancer bv disease
Risk of subfertility Disease/Treatment
Low Acute lymphoblastic leukaemia
Wilms' tumour
Soft tissue sarcoma: stage 1
Germ cell tumours (with gonadal preservation and no
radiotherapy)
Retinoblastoma
Brain tumour: Surgery only
Cranial irradiation<24Gy







Hodgkin's disease: 'alternating therapy'
Brain tumour: Craniospinal radiotherapy
Cranial irradiation>24Gy
High Total body irradiation
Localised radiotherapy: pelvic/testicular
Chemotherapy conditioning for bone marrow transplant
Hodgkin's disease: alkylating agent based therapy
Soft tissue sarcoma: metastatic
Low risk is assessed at <20%, high risk as >80%. Medium risk is difficult to quantify. Males are more
susceptible to subfertility following chemotherapy than females, although females may be at risk of
premature menopause. It is emphasized that this table represents a guide only, and is based on
gonadotoxicity of agents involved along with long term follow up ofpatients. In addition, the list of
diagnoses is not folly comprehensive, due to the variability of disease sub-types and stage at diagnosis.
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1.2). As can be seen, treatment for Hodgkin's disease with alkylating agent-based
therapy is profoundly gonadotoxic, as discussed above. Conditioning prior to bone
marrow transplantation, with high dose chemotherapy and total body irradiation, also
carries a substantial risk ofgonadotoxicity, as do treatment ofmetastatic sarcoma and
testicular irradiation. In contrast, current treatment for Acute Lymphoblastic Leukaemia
(ALL), the commonest malignancy in childhood and adolescence, represents a relatively
low risk ofgonadotoxicity.
It is important to note that treatment protocols for malignant disease are continually
evolving, in order to improve survival and reduce adverse effects. Whereas treatments
for ALL and neuroblastoma have intensified over the past decade, the management of
Non-Hodgkin's Lymphoma and hepatoblastoma, for example, has become less intensive.
In addition, as more is known about the biology ofmalignant disease, there is an
increasing trend to stratify treatments according to risk of relapse. Therefore, this
assessment of risk represents a guide, which needs to be continually reviewed in the light
of ongoing research.
To complicate matters further, there are reports of patients having received sterilizing
treatment who have subsequently demonstrated recovery ofspermatogenesis (Marmor
and Duyck, 1995). This not only has implications for counselling with regards to
infertility, but also demonstrates the importance of discussing contraception with adult
patients whose fertility status is uncertain.
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In view of these uncertainties, informing children and their families about future fertility
prospects can be very difficult. Long term follow-up of these patients must include
appropriate discussion and assessment of fertility.
Determining the impact of cancer treatment on gonadal function currently involves
regular clinical assessment ofpubertal status, biochemical assessment of plasma
gonadotrophins and testosterone, and analysis ofsemen specimens.
Testicular enlargement is the initial sign ofpuberty in boys, followed by penis
enlargement and the development ofpubic hair (Tanner, 1962). As discussed earlier,
many male patients following gonadotoxic therapy will have preserved Leydig cell
function and therefore develop normal secondary sexual characteristics. Their testes,
however, will be small and atrophied, with a loss of tubular volume (Fig 1.6), suggestive
of reduced sperm production (Siimes and Rautonen, 1990). On clinical examination,
using the Prader orchidometer, a testicular volume of 12ml or less in a postpubertal male
is likely to be associated with azoospermia.
However, in prepubertal children, clinical assessment such as this is non-contributory and
biochemical assessment is unreliable because the hypothalamic-pituitary-gonadal axis is
relatively quiescent in this age group. Thus it is currently not possible to detect gonadal
damage early, due to the lack of a sensitive marker of gonadal function in prepubertal
children.
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Figure 1.6 Small. Atrophied Testis following Gonadotoxic Therapy
Normal testis on left, with atrophied testis following gonadotoxic therapy on the right
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There is currently much interest in plasma inhibin B as a potential marker of
gonadotoxicity in this age group. Inhibin B is secreted predominantly from the Sertoli
cells and is involved in negative feedback regulation ofFSH; it is also a good indicator of
the status ofspermatogenesis in adulthood (Anderson and Sharpe, 2000). There is some
evidence to suggest that gonadotoxic chemotherapy is associated with a reduction in
inhibin B levels in adults (Wallace et al, 1997), presumably indicating reduced sperm
production (Anderson and Sharpe, 2000). However, this relationship has not been clearly
demonstrated in prepubertal boys (Crofton et al, 2003). Because spermatogenesis has not
yet been initiated, and circulating FSH levels are low, the role of inhibin B before puberty
is likely to be rather different than in adulthood (Anderson and Sharpe, 2000). It
therefore remains to be seen if inhibin B will become a useful tool in fertility assessment
of these children in the future.
1.5 Options for Fertility Preservation
1.5,1 Semen Crvopreservation
Currently the only established option to preserve fertility following gonadotoxic therapy
is cryopreservation ofspermatozoa prior to commencing treatment. Patients for whom
this procedure is suitable must be peri- or post-pubertal and sexually mature. In addition
they must be able to give consent for the storage of the specimen.
In the paediatric population, cryopreservation of semen is particularly problematic.
Sperm banking has, at least in the recent past, not been universally practiced in Paediatric
Oncology centres, and there are few suitable 'adolescent-friendly' facilities. In many
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circumstances treatment of the cancer needs to start as quickly as possible following
confirmation of the diagnosis and thus obtaining a semen specimen is required relatively
soon. After having received such devastating news regarding the diagnosis, it can often
be very difficult for teenagers to then discuss fertility and future children and
subsequently go on to produce a semen specimen. On the positive side, however, many
patients and their families may derive benefit from open discussion regarding fertility,
particularly as this places emphasis on looking to the future and provides reassurance that
curative treatment is the aim (Wallace and Thomson, 2003).
The semen specimen is usually produced by masturbation but can also be obtained using
rectal electrostimulation techniques under anaesthetic. Should it not be possible to obtain
an ejaculate, epididymal aspiration or testicular biopsy, in sexually mature men, can be
used to retrieve sperm.
The specimens produced are often ofpoor quality, particularly in the adolescent age
group (Postovsky et al, 2003). Many of these adolescent patients may have only recently
commenced spermarche which may partially explain this, but many other factors are
involved including the effects of the disease itself, as discussed above. In addition
psychological stress, often observed at this difficult time, can certainly impair semen
quality (Clarke etal, 1999). The sperm can then sustain further damage as a result of the
freeze-thawing process used for cryopreservation, which can impair sperm motility
(Alvarez and Storey, 1992) and cause damage to chromatin structure and sperm
morphology (Hammadeh et al, 1999).
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Following cryopreservation, stored spermatozoa are subsequently used to produce
offspring via In Vitro Fertilisation (IVF). With advances in assisted reproduction
techniques, in particular Intracytoplasmic Sperm Injection (ICSI), which involves the
injection of a single spermatozoan directly into an oocyte, the problems of low sperm
numbers and poormotility may be circumvented (Chen etal, 1996; Rosenlund etal,
1998).
Semen cryopreservation should be offered to all suitable patients prior to commencing
treatment but, as discussed, this process can be problematic. In addition this option is
obviously not applicable to the pre-pubertal patient and thus other methods of fertility
preservation must be considered. These alternative options all remain experimental at the
present time.
1.5,2 Testicular Tissue Harvesting
As discussed earlier, prepubertal testes do not complete spermatogenesis and thus do not
produce mature spermatozoa. However, they do contain the diploid stem germ cells from
which haploid spermatozoa will ultimately be derived. Therefore in theory, testicular
tissue could be harvested from a biopsy and stored, either as a segment of tissue or as
isolated germ cells, prior to sterilizing cancer therapy. Following cure and on entering
adulthood this tissue could be thawed and used in one of two ways in order to produce
offspring. Firstly, the stored germ cells could be re-implanted into the patient's own
testes in order to restore natural fertility, a procedure known as Germ Cell
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Transplantation. Alternatively the stored stem cells could be matured in vitro until they
are able to achieve fertilisation using ICS!
1.5.2.1 Germ Cell Transplantation
Germ cell transplantation was pioneered in mice by Brinster and colleagues in 1994
(Brinster and Zimmermann, 1994). Following the injection ofgerm cell suspensions
from donor mice into genetically sterile, immune-deficient mice, restoration of
spermatogenesis was observed from the donor stem cells. Similar results were also
demonstrated in recipient mice that had received sterilising treatment with busulfan.
Subsequently, in addition to this heterologous transplantation, successful transfer ofgerm
cells between species has been demonstrated, with rat spermatogenesis noted following
transplantation of rat germ cells into the seminiferous tubules of the mouse (Clouthier et
al, 1996). Germ cell transplantation between phylogenetically more distant species, such
as from rabbits and dogs into mice, has not been successful (Dobrinski et al, 1999),
perhaps because the microenvironment is not suitable for the proliferation ofdonor
spermatogonia. However, spermatogenesis has become established following xeno-
grafting of testicular tissue from mice, pigs and goats into castrated, immunodeficient
mice (Honaramooz et al, 2002).
Whilst the aforementioned studies have been essential in developing germ cell
transplantation, the clinical application of this technique in oncological patients would
almost certainly require successful autologous germ cell transplantation. Although there
have been promising results in primate models (Schlatt etal, 1999), beneficial effects
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have been difficult to demonstrate because of the inherent difficulty in confirming the
origin of subsequent spermatogenesis in these experiments (Schlatt et al, 2002).
Although this technique has potential benefit to survivors of childhood cancer, a number
ofproblems first need to be overcome, as discussed later.
1.5.2.2 In vitro Germ Cell Maturation
Maturing germ cells in vitro, stimulating their differentiation into spermatozoa, would be
particularly useful in patients who have received profoundly gonadotoxic therapy and in
whom the supporting Sertoli cells would be unable to support spermatogenesis. Nagano
et al (1998) demonstrated that mouse spermatogonial stem cells could survive for up to
four months in culture, retaining the ability to commence spermatogenesis following
transplantation back into a recipient. In addition, Tesarik etal (1999) reported the
restoration of fertility following in vitro spermatogenesis, although this has yet to be
confirmed by others. However, this process involved in vitro maturation of the later
stages of spermatogenesis rather than development from stem cells. Indeed, it appears
unlikely that in vitro maturation ofdiploid stem cells into haploid spermatozoa will be
technically possible in the near future.
1.5.2.3 Problems with Application of these Techniques
Whilst these techniques, once fully developed, have enormous potential and offer hope to
childhood cancer survivors at risk of infertility, these procedures are associated with a
number ofproblems that must be overcome before application in a clinical setting.
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Firstly, obtaining the testicular tissue would require an additional surgical procedure
following confirmation of the diagnosis and prior to the commencement ofany cytotoxic
treatment. This would necessitate a further general anaesthetic, although in practice it
should be possible to combine the testicular biopsy with other interventions required at
this time. In addition, the procedure itself could result in damage to the testis, for
example with bleeding and infection of the biopsy site. The prepubertal testis would be
particularly vulnerable due to its small size in this age group.
Secondly, autologous germ cell transplantation requires tissue that was removed from a
patient with cancer prior to treatment to be returned to the patient following cure. There
is, therefore, a genuine risk of reintroducing malignant cells, with potentially fatal
consequences. This is unlikely to occur with malignancies such as Hodgkin's disease,
which is often localised at presentation, but the risk would be substantial with
haematological malignancies (Jahnukainen etal, 2001), where the testes can act as
sanctuary sites for leukaemic cells. Indeed, any theoretical risk of returning cancer cells
following treatment, however small, would not be acceptable.
In order to circumvent this problem, it is likely that the germ cells, and in particular the
stem cells, from the testicular biopsy would need to be isolated prior to transplantation.
This would be safer and more acceptable than the use ofsemi-purified cell populations of
germ cells and somatic cells as used in transplantation in the rodent models discussed
above. However, the term 'stem cell' is a functional description as, at present, there are
no specific morphological, antigenic or biochemical criteria to identify these cells.
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Although stem cells do express certain surface antigens, such as a-6 and P-l integrins
(Shinohara et al, 1999), which would allow purification using magnetic cell sorting (von
Schonfeldt et al, 1999), other progenitor cells including haemopoietic cells also express
these antigens, and thus these markers will not be specific enough to exclude malignant
cells. For purification to be effective, specific antibody probes must be developed in
order to distinguish germ stem cells from other cells.
A further issue to be resolved before clinical application of these techniques is that of the
cryopreservation process. Cryopreservation ofmature, haploid spermatozoa is well
established. However, there are substantial biological differences between these cells and
undifferentiated, diploid stem cell spermatogonia, and thus the requirements of successful
freezing and thawing differ considerably. Glycerol is used as the preservative of choice
for ejaculated spermatozoa. However earlier germ cells, with proportionately larger
amounts ofcytoplasm, are more successfully preserved using dimethylsulphoxide
(DMSO) as the cryoprotectant (Avarbock etal, 1996). Despite this potential, the safety
ofDMSO in clinical use requires further evaluation prior to human application. Further
studies are therefore needed on the optimal cryopreservation process for human testicular
stem cells.
For germ cell transplantation to be successful, sufficient numbers of stem cells must be
injected into the testes. It has been estimated that 104 germ cells isolated from an adult
rodent testis contain as few as 2 stem cells (Meistrich and van Beek, 1993). Experiments
using murine models have demonstrated that the seminiferous tubules of recipient mice
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testes have a volume ofapproximately 1 Op.1. Since cell concentrations of 1 -2 x 108 cells
per ml can be injected, the recipient mouse will only receive approximately 200-400 stem
cells in a transplant (Brinster and Nagano, 1998). There is thus a need to develop an in
vitro enrichment system that will safely augment stem cell numbers following harvesting
and isolation, thus improving the cell yield returned to the patient. Nagano etal (1998)
have demonstrated successful in vitro culture ofmouse stem germ cells, and thus
enrichment is likely to be feasible. However, because of the low numbers ofstem cells
that are likely to be returned, it may be that patients in whom germ cell transplantation is
successful will still only be oligospermic rather than having normal sperm counts. They
will therefore still require assisted reproduction in order to produce offspring.
Following harvest, stem cell isolation, cryopreservation and enrichment, the cells then
need to be returned to the testes. Although this has been successfully performed in
animal models as discussed above, the procedure for transplantation into the human testis
remains unclear. The three main routes of re-infusion used previously are multiple
microinjections into superficial seminiferous tubules, injection into the rete testis or
injection into the efferent ducts. Although all of these techniques have been successful in
the mouse (Ogawa etal, 1997), the most effective method in larger testes, including
humans, is likely to be injection into the rete testis under ultrasound guidance (Schlatt et
al, 1999). Injection into this area allows a much larger volume to be infused. This
technique is particularly successful in immature or regressed testes because of the lower
intratubular fluid pressure, which can impair the injection into fully active testes. As the
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testes in cancer patients can be regressed secondary to cytotoxic treatment, this technique
is certainly promising, although still needs to be refined prior to clinical application.
As can be seen, germ cell transplantation has potential, but there are a number of
problems with the technique that need to be resolved. It could be argued that the safest
method would be xenografting testicular tissue, for example into nude mice as
demonstrated by Honaramooz et al (2002). In particular this eliminates the risk of re¬
introducing malignant cells. There would, however, be a risk of inter-species transfer of
potentially pathogenic microorganisms. In addition, and perhaps more importantly, this
process would raise ethical difficulties, which may limit its clinical application.
The technique of in vitro maturation of stem cells shares many of the problems discussed
above but also circumvents the risk of re-introducing malignant cells, thus making this
procedure potentially highly beneficial in this patient group. However, as discussed
above, the technology to enable this maturation to occur may be some time away.
Although ICSI has been successful using nuclear material from a round spermatid
(Tesarik etal, 1995) and thus the maturation to spermatozoa need not be complete, the
ability to artificially mature a diploid stem cell into a suitable haploid cell is not possible
at the present time.
Finally, ICSI itself is not without potential complications. Because ICSI involves the
injection of nuclear material directly into an oocyte, some of the natural mechanisms that
normally prevent sperm with defective DNA being involved in fertilisation are bypassed.
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In addition, the oocyte fertilized may itselfbe abnormal. There is, therefore, genuine
concern that DNA and chromosomal abnormalities are more likely to be passed on to
offspring produced with such techniques. Indeed, a number of large follow up studies
have demonstrated an increase in chromosomal abnormalities, particularly of the sex
chromosomes, in offspring bom using ICSI (Tarlatzis and Bili, 2000; Bonduelle et al,
2002a). However, rather than the technique itselfpredisposing to these abnormalities, the
increased incidence is felt to reflect the higher rate of constitutional chromosomal
anomalies observed in infertile couples utilizing ICSI, particularly on the paternal side
(Bonduelle et al, 2002a).
Transmission of constitutional chromosomal anomalies is less likely in cancer survivors
because their infertility is secondary to gonadotoxic treatment. However, concerns have
been raised that the mutagenic potential of cancer therapy could predispose the offspring
of these patients to congenital abnormalities, and even cancer themselves. A large
epidemiological study has failed to demonstrate any such link (Hawkins et al, 1989),
except in those with familial malignancies, although these offspring resulted from natural
conception. A recent study (Thomson etal, 2002a) investigated the integrity of
spermatozoal DNA in men who had undergone treatment for childhood cancer. These
sperm did not carry a greater burden ofdamaged DNA as compared to age-matched
controls, providing some reassurance with regards to the use ofspermatozoa from
oligospermic men who have survived childhood cancer.
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A further concern ofoffspring born using ICSI and IVF is the risk of congenital
malformations. A number of large follow up studies have demonstrated no difference
between ICSI and IVF in this regard, and indeed have suggested a comparable rate of
major malformations to that seen following natural conception (Bonduelle etal, 2002b;
Palermo et al, 2000). Other studies have suggested an increased malformation rate,
although have attributed this to the higher rate ofmultiple births seen following assisted
reproduction (Wennerholm et al, 2000).
However, interpretation of studies such as these can be problematic due to the inherent
difficulty in obtaining appropriate control data for comparison, as maternal age, parity,
sex of the infant and multiple births will affect the incidence of these abnormalities. In
addition, variability exists between definitions ofmajor and minor birth defects. In
contrast to the aforementioned studies, Hansen et al (2002) suggested that infants
conceived using ICSI or IVF are twice as likely to suffer a major birth defect, and that
this risk remained significant even allowing for these factors. Infants born of such
techniques will be followed up more closely and thus one could argue that defects are
more likely to be diagnosed in this cohort. However, the authors included defects
diagnosed up to one year of age, at which time the majority ofmajor defects would have
been detected in all patient groups. In addition, there is evidence to suggest that babies
bom following assisted reproduction are at greater risk of low and very low birth weight
(Schieve et al, 2002). Although this can again be explained, in part, by an increase in
multiple births, it can also be a feature of singletons bom with this technology.
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Further long-term prospective studies are required to obtain accurate information on these
children. If an increased risk ofabnormalities is genuine, consideration must be given to
the aetiology of these problems. The difficulty in identifying causative factors is that
couples utilizing these techniques are inherently more at risk prior to fertility treatment,
and thus the effect of the procedure itself can be difficult to elucidate. As discussed
above, these risk factors may be less likely in survivors of childhood cancer.
In summary, both germ cell transplantation and in vitro maturation do offer hope for
fertility preservation in males treated for cancer, particularly those in the prepubertal age
group. However, in view of the significant concerns that exist with both techniques, it
may be some time before their clinical potential is realized and they form part of the
routine management in these patients.
1.5,3 Hormonal Manipulation
Cytotoxic treatment, as mentioned previously, acts principally on rapidly dividing cells.
As the testis demonstrates much cellular activity it is therefore prone to this damage and
gonadotoxicity may result. In view of this, it has been postulated that inducing testicular
quiescence could prevent gonadal toxicity, by making germ cells less vulnerable to the
cytotoxic effects. This may represent an alternative, and potentially more acceptable
method of fertility protection in prepubertal boys treated for cancer.
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1.5.3.1 Rodent Models
Studies investigating this technique using rodent models have produced very encouraging
results. Ward et al (1990) induced suppression of the hypothalamic-pituitary-gonadal
axis using a GnRH agonist. Pulsatile GnRH is required for normal gonadal function, but
ifadministered at a supraphysiological dose in a non-pulsatile, chronic manner,
suppression of the hypothalamic-pituitary-gonadal axis will occur via down-regulation of
pituitary GnRH receptors. When administered to rats prior to treatment with
procarbazine, enhanced recovery of spermatogenesis was demonstrated, as compared to
control animals. Similar protection of spermatogenesis has also been demonstrated using
other methods of suppressing the reproductive axis, including treatment with testosterone,
testosterone and oestradiol (Parchuri etal, 1993), GnRH antagonists and anti-androgens
such as flutamide (Kangasniemi etal, 1995). In addition, these methods have been
protective against other gonadotoxic agents such as cyclophosphamide (Meistrich et al,
1995) and radiotherapy (Kurdoglu etal, 1994), suggesting that the mechanism of
protection is not specific to particular modes of cytotoxic therapy.
A number of issues have arisen from these experiments. Firstly, the time required to
suppress the reproductive axis is an important factor if this procedure is to be utilized in a
clinical setting. Many of the studies discussed above involve hormonal manipulation
commencing a number ofweeks prior to administration of the cytotoxic agent. Cancer
treatment should, in general, start as soon as possible following confirmation of the
diagnosis, and therefore this delay would not be acceptable in patient management.
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Secondly, the timing of suppression of the reproductive axis in relation to the cytotoxic
damage has provoked many questions regarding the mechanism ofgonadal protection.
Meistrich and Kangasniemi (1997) demonstrated that hormonal manipulation with a
GnRH antagonist or testosterone led to the successful recovery of spermatogenesis in rats
even when given after irradiation. Similar results have also been observed with hormonal
treatment after the administration ofprocarbazine (Meistrich et al, 1999). Whilst this
would circumvent the concerns highlighted above regarding the delay in cancer
treatment, these studies suggest that the original hypothesis of gonadal protection simply
involving a reduction in the susceptibility ofgerm cells is incorrect.
There is evidence, based on rodent studies, to suggest that azoospermia following
cytotoxic therapy does not necessarily result from complete depletion of spermatogonia,
but can be secondary to a failure ofsurviving spermatogonia to replicate and differentiate
(Kangasniemi et al, 1996). It has therefore been postulated that the recovery of
spermatogenesis following hormonal treatment observed in these rodent models is due to
stimulation of differentiation of surviving spermatogonia. A consistent feature observed
in recovery of spermatogenesis is a reduction in intratesticular testosterone (Meistrich
and Kangasniemi, 1997; Shetty etal, 2000), and it has been suggested that this relieves
the block ofdifferentiation, perhaps by alterations in the endocrine and paracrine
environment of the testes. This subsequently allows the restoration of spermatogenesis.
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1.5,3.2 Human and Primate Studies
Despite the success of these techniques in rodent models, clinical trials of hormonal
manipulation in male patients receiving gonadotoxic therapy have thus far failed to
demonstrate any benefit. Administration ofa GnRH analogue prior to and during
treatment for lymphoma has been ineffective in conserving fertility (Johnson etal, 1985;
Waxman et al, 1987). Interestingly, the use ofGnRH analogues to suppress the
hypothalamic-pituitary-ovarian axis in both female patients and female primate models
has demonstrated gonadal protection from alkylating agents (Ataya et al, 1995;
Blumenfeld et al, 1996).
Subsequent to the earlier trials ofmale patients, and in view of the studies discussed
above regarding the optimal timing of hormonal treatment, Thomson et al attempted to
restore spermatogenesis in seven men rendered azoospermic following treatment for
childhood cancer (Thomson et al, 2002b). However, after suppression of the
hypothalamic-pituitary-gonadal axis with testosterone and medroxyprogesterone acetate
the men remained azoospermic on reassessment, and their testes, on biopsy, lacked germ
cells. Perhaps in this study the hormonal treatment was initiated too long after the
cytotoxic therapy. In addition, the lack of success may be because the initial testicular
insult was too severe, and that this technique may be more beneficial in patients with less
severe gonadal damage in whom some spermatogonial stem cells are preserved following
cytotoxic treatment. However, it is difficult to justify further clinical trials in this area
until the mechanism ofgonadal 'protection' is better understood.
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Indeed, extrapolating evidence from rodent models to clinical trials assumes that both the
physiology of spermatogenesis and the mechanisms of gonadotoxic damage are similar in
both species. However, as discussed previously, there is evidence to suggest that
significant inter-species differences do exist, and that perhaps other primates would be
more appropriate models in which to study spermatogenesis in this regard (Weinbauer
and Nieschlag, 1989; Sharpe etal, 2000). Certainly, hormonal manipulation in the
macaque does not prevent radiotherapy-induced gonadal damage (Kamischke et al,
2003).
1.5,3.3 The Marmoset as a Model for studying Testicular Development
The common marmoset (Callithrixjacchus), a NewWorld primate (Fig 1.7), represents a
useful model for studying prepubertal testicular development.
Firstly, the marmoset demonstrates similar phases of testicular development as the human
(Sharpe et al, 2000). The testes are descended into the scrotum at birth, or within days of
birth. During the neonatal period the marmoset demonstrates a surge of testosterone (Fig
1.8), as occurs in the human. As discussed previously, the function of this hormonal
activity is uncertain at present. Following this, the hypothalamic-pituitary-gonadal axis
becomes relatively quiescent during a relatively prolonged prepubertal phase (Fig 1.8).
The marmoset then commences puberty at around 45 weeks ofage, with a concomitant
increase in hormonal activity, subsequently entering adulthood at around 75 weeks of
age.
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Figure 1.7 Adult Marmoset, Callithrix iacchus
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Secondly, the marmoset displays similarities in its organization of spermatogenesis to the
human (Miller et al, 2000). These similarities relate both to the stages and duration of the
spermatogenic cycle, and to the arrangement of these stages along the seminiferous
tubule. Of those primates studied, spermatogenesis in the marmoset most closely
resembles that in the human and chimpanzee, and is certainly more comparable than
spermatogenesis in the rat. It is also established that spermatogenesis in the marmoset is
of similar poor efficiency to that observed in the human (Sharpe et al, 2000).
A further advantage of using the marmoset as an animal model is that they are usually
bom as twins, which are dizygotic but share a common placenta. Therefore any
intervention in one animal can be compared with a genetically distinct, but otherwise
similar control animal. This reduces the number of animals required to achieve
statistically significant results, and is particularly important as considerable inter-animal
variability can occur.
1.5,3.4 Prepubertal Testicular Development in theMarmoset
Using this marmoset model, Kelnar et al (2002) investigated the prepubertal phase of
testicular development. This study was based on the immunoexpression of a number of
antigens within prepubertal marmoset testes.
Functional development of Sertoli cells, based on the expression of sulphated
glycoprotein-2 and androgen receptor, and of Leydig cell activity, based on the
expression of 3f3-hydroxysteroid dehydrogenase, was demonstrated prepubertally. In
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addition, proliferation ofgerm cells was noted at this age, indicated by the
immunoexpression ofproliferating cell nuclear antigen (PCNA). This provides further
evidence that the prepubertal testis is not quiescent, and improves our understanding of
why the testis is susceptible to cytotoxic damage at this age group.
In addition, this study also investigated the effects of treatment with a GnRH antagonist
on the prepubertal marmoset. It was found that this treatment, for ten weeks during the
prepubertal phase between 25 and 35 weeks ofage, largely prevented many of the
changes highlighted above. However, quite unexpectedly, the proliferation ofgerm cells,
as assessed by the PCNA labeling index of spermatogonia, was unaffected by
administration of the GnRH antagonist, when compared to control animals (Kelnar et al,
2002). This suggests that spermatogonial, and possibly stem cell, proliferation, at least in
prepubertal primates, is in fact gon&doiToyhm-independent.
If this finding were to be confirmed it would suggest that hormonal manipulation based
on suppression of the gonadotrophin axis is unlikely to be successful in alleviating
gonadotoxic damage secondary to cancer treatment, and thus may explain the failure of
previous studies using this technique in primates.
This project aimed to investigate further the hypothesis that prepubertal spermatogonial
proliferation in primates is gonadotrophin independent, using alternative proliferative
markers. Assuming that this was confirmed, the intention was then to investigate what
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factors do regulate spermatogonial proliferation at this age, with the hope that these
would offer novel targets for gonadal protection during cytotoxic therapy.
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Chanter 2
Immunohistochemistrv- Basic Principles and Techniques Used
2.1 Introduction
The basis of this study is the immunohistochemical detection ofproteins present in
fixed marmoset testis tissue. Immunohistochemistry was selected as the most
appropriate method of investigation as it not only establishes the presence of certain
proteins in a tissue, but also allows the localisation of the protein within that tissue.
Indeed, in order to elucidate what factors act on a subtype of cells (spermatogonia and
stem cells) within a multicellular tissue (testis), immunohistochemistry is the only
viable approach. In addition, many methods of investigation that have contributed to
our understanding of spermatogenesis in rodents, such as gene knockout models, are
not applicable to primate species.
The essential factor common to all immunohistochemical techniques is the primary
antibody. Specific antibodies to increasing numbers of tissue antigens are now
available, which has contributed both to the quantity and quality of
immunohistochemical techniques now possible. In addition to the antibodies
themselves, refinements to many areas of the process have enabled
immunohistochemistry to have widespread application, both in research and as a
diagnostic tool in cellular pathology. For example, the use of enzyme labelling has
enabled cellular morphology to be viewed in conjunction with antibody localisation.
In addition, the use ofantigen retrieval methods have led to the detection of antigens
not previously possible in sections fixed in formalin.
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However, despite these improvements it is important to note that the lack of
immunostaining is not proof of absence of the antigen, as the antigen may be present
but not detectable with the method used. Immunohistochemical methods require to be
optimised for individual tissues, with the ability to detect the presence of an antigen
balanced against the conservation of cellular morphology.
This chapter is not intended as a comprehensive overview of immunohistochemistry,
but rather to focus on areas relevant to the present study. The methods discussed
relate to those used for the investigation of antigens within the marmoset testis,
including the use of immunofluorescence and alternative methods of double staining.
Background (non-specific) staining is also discussed, as this was found to be the
major problem with the immunohistochemical analysis of the marmoset tissue
studied.
2.2 Principles of Immunohistochemistrv
Immunohistochemistry is a technique for identifying cellular or tissue constituents
(antigens) by means of their specific binding to an antibody. The site of this binding
can then be detected, either by direct labelling of the antibody, or by use of a
secondary labelling method.
2,2.1 Antibodies
IgG is the most common subclass ofprimary antibody used in immunohistochemistry,
and is produced in both polyclonal and monoclonal forms. Polyclonal antibodies are
produced by immunising an animal with a specific molecule bearing the antigen of
interest (De Mey and Moeremans, 1986). An immune response is generated, and the
55
antibodies produced can be harvested from the animal's blood. Because numerous
clones ofplasma cells are produced, the antibodies have slightly different specificity,
reacting to various epitopes on the antigen against which they are raised. In contrast,
monoclonal antibodies are the product of an individual clone ofplasma cells and are
therefore identical, reacting to a specific epitope against which they are raised (Gatter
et al 1984). After an immune response has been generated, B-lymphocytes from
spleen or lymph nodes are harvested and fused with non-secreting mouse myeloma
cells. This hybrid results in the production of specific antibody from an immortal cell
line. Unlimited quantities of antibody, which is both pure and highly specific, can
therefore be obtained.
Monoclonal antibodies demonstrate high homogeneity, with little variability between
batches. Consistent results are therefore reliably obtained with antibodies produced in
this manner. However, the conditions for the use ofmonoclonal antibodies are highly
specific, and must be identical to those used in quality control on production of the
antibody initially. In addition, polyclonal antibodies may still detect antigens that are
not adequately preserved by tissue fixation, whereas the particular epitope with which
the monoclonal antibody interacts may not be preserved.
2,2,2 Antibody Binding
The affinity of antibody binding to the antigen is determined, to a large extent, by the
specificity of the antibody used. Antigen-antibody reactions are reversible and thus
immune complexes may dissociate during the washing cycles used in
immunohistochemistry. Antibodies with higher affinity are advantageous in this
regard, as this is less likely to occur.
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Under ideal conditions, antibodies react with their antigen very rapidly. However, in
immunohistochemistry, conditions such as tissue fixation, antibody concentration and
temperature affect the rate of this reaction. Because equilibrium between antigen-
bound and free antibody is rarely achieved, long incubation periods with more dilute
primary antibody are generally used. The use ofmore concentrated antibody
preparations frequently results in non-specific background staining, affecting the
interpretation of results. When investigating the immunoexpression of an antigen
within a particular tissue using a particular primary antibody, it is therefore essential
to initially use a range of antibody concentrations, in order to identify the conditions
for optimal staining.
2.2,3 Labelling
In order for the site of antigen-antibody reaction to be visualised, the antibody used
must be labelled. Enzymes are the most widely used labels in immunohistochemistry,
and incubation with a chromogen produces a stable, coloured reaction end product,
suitable for visualisation under the light microscope.
Horseradish peroxidase is the enzyme most frequently used and, in combination with
3,3-diaminobenzidene tetrahydrochloride (DAB), yields a stable, dark brown reaction
end product (Graham and Karnowsky, 1966). However, endogenous peroxidase
activity within the tissue, present in a number of sites such as neutrophils and other
myeloid cells, must be blocked before application of the primary antibody. Hydrogen
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peroxide in combination with methanol (Streefkerk, 1972) is used as the blocking
procedure in this study.
2.2.4 Staining methods
The simplest method of staining is the direct technique, in which the primary antibody
is enzyme-labelled, and this reacts directly with the antigen in the tissue (Fig 2.1).
This method is quick and non-specific reactions are limited. However, because signal
amplification cannot be achieved, the sensitivity of this method is insufficient for
most immunohistochemical studies.
Sensitivity can be improved with the use of an indirect, two-step method. Here, the
primary antibody binds to the antigen within the tissue as before. However, the
enzyme label is not attached to the primary antibody but to a secondary antibody,
which itself binds to the primary antibody (Fig 2.2). This secondary antibody must be
directed against immunoglobulins from the same species in which the primary
antibody was raised. Several secondary antibodies are likely to react with a number
of different epitopes of the primary antibody, and therefore more enzyme molecules
will be attached to each target site, thus amplifying the signal obtained. Undesired
reactions may occur if the secondary antibody cross-reacts with immunoglobulins
present within the tissue specimen. However, the use of a secondary antiserum that
has been preabsorbed with immunoglobulins from the species under investigation can
eliminate this cross-reactivity.
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Figure 2.2 Two-step indirect method
Enzyme-labelled secondary antibody
reacts with primary antibody bound to
tissue antigen
Figure 2.3 Avidin-Biotin Technology
Avidin- or streptavidin-biotin enzyme





Figure 2.4 Chain polymer-conjugated
Technology (Envision)
A spine molecule, which contains an
average of 10 molecules of secondary
antibody and 70 molecules of enzyme,
binds to primary antibody
Figure 2.1 Direct Method
Enzyme-labelled primary antibody












If required, further amplification can be obtained by the addition of an enzyme-
labelled tertiary antibody to the complex. This three-step indirect method can be
useful for staining antigens with a limited number of epitopes.
Many immunohistochemical staining methods now use avidin-biotin techniques,
which rely on the high affinity of the glycoprotein avidin, or streptavidin, for biotin, a
low molecular weight vitamin. The principle is identical to the two-step indirect
method, except the secondary antibody is not enzyme-labelled but is biotinylated.
The enzyme label is attached to an avidin-biotin complex, and this binds to the biotin
on the secondary antibody (Fig 2.3). This signal amplification results in increased
sensitivity of detection (Hsu et al, 1981). The main problem with this technique is
non-specific staining from endogenous biotin, which can affect the interpretation of
results.
More recently, systems using chain polymer-conjugated technology have been
developed. An inert dextran molecule acts as a spine, onto which both enzyme labels
and secondary antibody can be attached (Fig 2.4). On average, 70 molecules of
enzyme and 10 molecules of antibody can be attached to the spine, allowing even
greater sensitivity of detection. In addition, the problem of non-specific binding of
endogenous biotin is eliminated. This technology is now commercially available, and
the system used in this study is Envision (DAKO, California, USA). However, at
present this system is only available for the detection of primary antibodies raised in
either rabbit or mouse, and therefore the avidin-biotin method is required for
antibodies raised in other species, such as the goat.
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2.3 Tissue Fixation
To enable reliable detection of antigens within a tissue, it is essential that these
antigens are adequately preserved. In addition, conservation of cellular morphology
is required to allow the precise cellular and sub-cellular localisation of those antigens
detected. Fixation achieves this by stabilizing proteins within the tissue, by the
formation of cross-links, and the methods employed depend on both the tissue itself
and the investigative technique to be used.
Although this cross-linking acts to stabilize proteins, it can also result in the 'trapping'
ofantigens, such that antibodies cannot physically access them in order to bind. The
longer and stronger the fixation, the more widespread is the cross-linking. Antigens
affected in this manner can be detected following antigen retrieval procedures, as
discussed in the following section, but tissue morphology can be impaired following
such techniques. This emphasises how immunohistochemical methods must be
optimised to ensure both adequate antigen detection and cellular morphology. Frozen
tissue avoids the problems of cross-linking, but as a consequence morphological
preservation is drastically impaired. The use of frozen tissue would therefore not be
suitable for the present studies, in which accurate localisation and identification of
specific sub-sets of spermatogonia is a prerequisite.
The marmoset testes used in this study were fixed in Bouin's solution for 5-6 hours,
and then embedded in paraffin. Bouin's solution is formaldehyde based, and achieves
fixation by reacting with basic amino acids to form cross-linking 'methylene bridges'.
This results in relatively low permeability to macromolecules, and means that
structures of intracytoplasmic proteins are not significantly altered (Fox etal, 1985).
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Although, as mentioned, some antigens may not be well demonstrated after fixation in
formaldehyde-based fixatives, these may be detected following antigen retrieval
methods, particularly if polyclonal antibodies are used.
2.4 Antigen Retrieval
Because the immunoreactivity of certain antigens can be affected by tissue fixation,
particularly by the use of formalin, numerous techniques have been developed to
improve the detection of these antigens, a process known as antigen retrieval.
Antigen retrieval has been reported following proteolytic digestion (Huang et al,
1976) and microwave heating (Shi et al, 1991). However, the study ofmarmoset
testis detailed here uses pressure-cooking as a heat-mediated antigen retrieval step, as
described by Norton et al (1994), because heating of the tissue is more uniform than
with microwave heating. In addition, more slides can be heated in one batch. This
heat treatment does not appear to significantly alter cellular morphology of fixed
tissue (McNicol and Richmond, 1998), although some loss of cellular architecture
will occur and therefore conditions must be optimised to minimize this disruption.
For antigen retrieval to be effective, the slides must be heated in an aqueous solution.
The solution used in the present study was most commonly a citrate buffer with a pH
of 6.0, although a glycine buffer with a pH of 3.5 was also used on occasions, and
alternative buffers can be effective. Optimising the method of retrieval for a
particular antigen in a particular tissue requires the use ofdifferent buffers, in order to
assess which is most appropriate.
62
The degree to which immunoreactivity can be restored is also related to the duration
of heating and the temperature attained. Sections in the present study were kept at
boiling point for 5 minutes, before being allowed to cool slowly over 20 minutes, as
this has been previously shown to be effective using this marmoset tissue (Kelnar et
al, 2002).
Whilst the exact mechanism of action ofantigen retrieval remains uncertain, it is felt
that these methods may be effective by breaking down some of the protein-protein
cross links induced by tissue fixation.
It is important to note that not all antigens require antigen retrieval before their
detection. In general, detection of antigens within the nucleus is improved with
antigen retrieval, whereas cytoplasmic antigens can often be detected without this
step.
2.5 Background Staining
Background staining is one of the most common problems encountered in
immunohistochemistry, and certainly caused difficulties in this study of the marmoset
testis (Fig 2.5).
Background staining may be specific, such as fibrinogen in blood vessels, or, as
demonstrated in Fig 2.5a, staining of elongate spermatid cytoplasm within post-
pubertal sections ofmarmoset testis, which can be a problem at this age. Another
common site of background staining in this tissue is the acrosome of spermatids.
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Figure 2.5 Examples ofBackground Staining observed in Marmoset Testis
(a) Section from adult
marmoset demonstrating
staining of cytoplasm of
elongate spermatids (lOx
magnification)





staining within the tissue
(20x magnification)
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Alternatively, background staining may be non-specific (Fig 2.5b), due to the
apparent affinity of certain tissue components. Non-specific staining is usually the
most problematic source, and is caused mainly by non-immunological binding of
antibody to certain sites within tissue sections via hydrophobic and electrostatic
sources (Kraehenbuhl and Jamieson, 1974). This binding can be of the primary
antibody or, more commonly, the secondary antibody, which can be particularly
problematic due to the considerable variability between batches. By blocking these
sites that have a non-specific affinity for antibodies, this background staining can be
reduced. This can be achieved by incubating the sections in immunoglobulin that will
bind to these sites but will not react with the primary antibody. Normal (diluted)
whole serum from the species in which the secondary antibody is raised is therefore
applied to the sections before application of the primary antibody. In addition, the
primary antibody itself is diluted in this normal whole serum. Lower concentrations
of primary antibody will also reduce the background, and with the more sensitive
staining methods discussed above, such as Envision, detection ofgenuine staining is
still possible. Further methods to reduce background staining include the addition of
a detergent such as Tween into the washes, in order to reduce the hydrophobic
interactions.
A further source ofbackground staining can be from endogenous enzymes. As
mentioned previously, endogenous peroxidase activity must be blocked before
application of the primary antibody, and this is usually achieved by incubation in
methanol and hydrogen peroxide. Biotin-based detection methods are susceptible to
background staining from endogenous biotin. Biotin is present in a variety of tissues,
including liver, kidney and lymphoid tissue, but is also likely to contribute to the
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background staining observed within the lumen of the seminiferous tubule of the
marmoset testis. Incubation of sections with avidin, followed by biotin, prior to
application of the primary antibody, reduces the background from this source (Wood
andWarnke, 1981).
Finally, background staining can be secondary to tissue damage, either by drying out
prior to fixation or by incomplete penetration of the fixative into the tissue (Fig 2.5c).
This generally appears as diffuse staining of all or most tissue elements within the
affected area.
2.6 The Use of Controls
The use of controls in immunohistochemistry is essential for validation of the results,
particularly with regards to the specificity of the primary antibody. False-positive
results can certainly occur with the use ofpolyclonal antibodies, because related
molecules may have antigenic components in common. Although this is less likely
with the use ofmonoclonal antibodies, non-specific cross-reactivity can still occur.
For immunohistochemical staining to be specific it must be shown that staining does
not occur in the absence of the primary antibody. Furthermore, staining should be
inhibited by adsorption of the primary antibody with the relevant antigen prior to its
use.
In practice, the following types of controls are routinely used in
immunohistochemistry. Firstly, negative controls involve a section treated identically
to all other sections, except for the omission ofprimary antibody. Any staining
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present on this tissue would therefore originate from an alternative source, such as the
secondary antibody, and thus interpretation of other sections investigated would be
problematic. Secondly, a blocking peptide can be used, in which the primary
antibody is preabsorbed with purified antigen, before application to the tissue.
Similarly, no staining should be observed on this section; this is probably the most
convincing control.
Finally, a positive control is advisable, as the absence of staining in a section does not
necessarily imply that the antigen is not present. Using tissue from the same animal
that is known to express the antigen under investigation will confirm that detection
with the primary antibody can be demonstrated. Selection of an appropriate tissue as
a positive control, however, can be problematic for some antigens, for example those
expressed mainly by 'stem cells'.
2.7 Double Staining
Double staining, as its name suggests, allows the immunohistochemical detection of
two antigens in the same section of tissue. Prior to the development of double
staining techniques, the analysis of serial sections was required. This process is both
laborious and co-expression can be difficult to visualise. In contrast, co-localisation
enables direct visualisation of the expression ofmultiple antigens in the same tissue
section.
If the two antigens are present within the same cellular compartment, co-localisation
will be demonstrated by the presence of a mixed colour. When the two antigens are
expressed in different cellular compartments, or in separate cells of the section, two
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separate colours will be observed. These colours should therefore be of sufficient
contrast to demonstrate this.
The double staining methods predominantly used in this study are based on
immunofluorescence, with analysis using a confocal microscope. However, double-
staining methods based on conventional immunoenzymatic techniques similar to
those discussed above can also be used.
2.7,1 Immunofluorescence
The basic principles of immunofluorescence, with specific antibody binding to an
antigen within the tissue, are identical to conventional immunohistochemistry
discussed above. However, instead of an enzyme-labelled secondary antibody that
produces a coloured end product with a chromogen, the antibodies are labelled with a
fluorochrome, which has the property of absorbing radiation in the form ofultraviolet
or visible light. This absorbed radiation causes the molecule to attain an 'excited
state', leading to electron redistribution and the emission of radiation of a different
wavelength. The emitted light is almost invariably of a longer wavelength and within
the spectrum detectable by the confocal microscope.
By using fluorochromes that emit light at different wavelengths, different antibodies
binding to different antigens can be visualised as separate colours, usually red, green
or blue. This produces excellent contrast when the antigens are expressed separately,
and allows simple visualisation if the antigens are expressed within the same cellular
compartment.
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The main drawback of analysing sections using immunofluorescence is the difficulty
visualising the cellular morphology. Although fluorescent counterstaining can assist
interpretation, the information obtained may be limited when compared to
conventional staining using light microscopy.
The sensitivity of detection can also be problematic using immunofluorescence. The
fluorescent signal can be amplified using enhancement with tyramide, as used in this
study. This is an enzyme-mediated detection method utilising horseradish peroxidase
to generate high-density labelling of a target protein (Bobrow et al, 1989). However,
although sensitivity of detection is increased, background staining also becomes more
prominent, particularly autofluoresence caused by formaldehyde fixation.
Finally, sections stained using immunofluorescence should be kept in cool
temperatures of around 4°C to prevent fading of the signal with time. In addition,
they should be protected from direct light, both during the staining procedure and for
subsequent storage.
2,7,2 Alternative Double Staining Methods
Double staining using conventional immunohistochemical methods can also be
achieved. As mentioned previously, incubation of horseradish peroxidase with DAB
produces a dark brown colour. However, enzyme labels on different antibodies
applied to the same section can be combined with alternative chromogens to produce
contrasting colours. Chromogens used in this study include Fast Blue, which
produces a blue colour, and NBT, which stains purple.
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It can be more difficult to visualise co-expression using these techniques, as compared
to immunofluorescence. However, this procedure does enable easier interpretation of
the staining pattern in context with the cellular morphology. In addition, if
immunopositive cells are infrequent within a section, such as stem cells within the





3.1 Animals and treatments
Animals were captive-bred common marmoset monkeys (Callithrixjacchus),
maintained in a colony that has been self-sustaining since 1973. A total of 16 infant
male marmosets aged 25 weeks of age were treated weekly with either vehicle
(controls; n=7), or with lOmg/kg of a potent long-acting Gonadotrophin Releasing
Hormone (GnRH) antagonist (Antarelix; Europeptides, Argentueil, France) (n=9)
until 35 weeks of age. Treatments were administered as weekly subcutaneous
injections in propylene glycol: water (1:1, v:v). As demonstrated in Figure 3.1, this
treatment is administered during the prepubertal 'infancy' phase of testicular
development in the marmoset. Although gonadotrophin levels cannot be measured in
this species, and thus the effectiveness ofGnRH antagonist treatment cannot be
directly assessed, this treatment has previously been shown to be effective. Complete
suppression of the neonatal testosterone surge has been achieved with this agent, as
evidenced by testosterone assays in this species (Lunn et al, 1994, 1997). In addition,
Sertoli and Leydig cell development in this species is impaired by such treatment
(Sharpe et al, 2000; Kelnar et al, 2002).
Because marmosets demonstrate considerable inter-animal variability that would
normally necessitate the use of large numbers of animals in experiments, the present
study, where possible, used male co-twins (n=4), which tend to be highly comparable.
Therefore, whilst one co-twin was administered the GnRH antagonist, the other co-
twin received vehicle as a control. This design enabled pair-wise comparison of data
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Figure 3.1 The timing of administration of the GnRH antagonist in relation to
normal testicular development in the marmoset





for each control and treated co-twin at 35 weeks of age, thus minimizing the number
of animals required for study.
To increase our understanding ofgerm cell proliferation at all stages of testicular
development, testes from animals killed at various time points, ranging from the
neonatal period through to adulthood, were also included in the study. These time
points were as follows: age 1-6 days («=10); 4 weeks («=4); 6 weeks («=5); 14 weeks
(«=3); 18-24 weeks (w=5); 58-62 weeks («=4) and adulthood (»=4). The variation in
numbers within each age group reflects the availability of animals at these time
points.
As discussed previously, the role of the neonatal testosterone surge, observed in a
number of primates including both man and marmoset, is uncertain. In order to
establish whether this hormonal activity may have a role in the regulation of
spermatogonia! proliferation, this study also included analysis of testes from 4-week-
old animals in which the neonatal testosterone surge had been suppressed by prior
administration of a GnRH antagonist. Analysis of co-twin pairs («=4) was used as
above, with one co-twin administered the GnRH antagonist on the day of birth, day 3,
day 7 and then at weekly intervals until week 4, at which time the animal was killed.
The other co-twin received vehicle as a control, at the same time intervals.
These studies were approved by the local ethics committee for studies in primates and
were performed according to the Animal Scientific Procedures (UK) Act (1986) under
Project Licence approval by the UK Home Office. The author is grateful for the
assistance ofDr R Sharpe in the administration of treatments to the animals involved.
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3.2 Tissue collection and processing
Animals were killed by injection of an overdose of sodium pentobarbitone (Euthatal;
Rhone Merieux Ltd, Harlow, Essex, UK). Testes with epididymides attached were
dissected free of connective tissue and immersion-fixed for 5.5 hours in Bouins, after
which the testis was dissected away from the epididymis and weighed. Fixed testes
were then processed overnight in an automatic processor and embedded in paraffin.
Testicular sections of 5fim thickness were then mounted on charged glass slides
(BDH Chemicals, Poole, UK). The author is grateful for the assistance ofDr R
Sharpe and Mr M Millar in preparing this tissue.
The tissue used for the experiments within this work was identical to that used by
Kelnar et al (2002), and was therefore archival in nature. The reason for this relates to
the availability ofmarmoset tissue, and highlights one of the difficulties in conducting
such work with primates.
3.3 Immunohistochemistrv
Details of all antibodies used in this study, including dilutions and methods used for
immunohistochemistry, are shown in Table 3 .1. The primary antibodies used had not
been previously applied to marmoset testis. Therefore, in order to establish the most
appropriate method, each antibody was initially evaluated using a range of dilutions
and under differing conditions ofantigen retrieval and detection. All incubations
were performed at room temperature, unless otherwise stated.
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Sections were dewaxed in xylene (BDH, Dorset, UK), rehydrated in graded ethanols
and washed in water. As detailed in Table 3.1, sections were, if required, subjected to
a heat-induced antigen retrieval step (Norton et al, 1994). As discussed previously,
the requirement for antigen retrieval was, at the outset, uncertain for the majority of
antibodies tested. Therefore each primary antibody was initially investigated both
with and without antigen retrieval. Buffers used for the antigen retrieval process were
0.01M citrate (pH 6.0) and 0.05M glycine (pH 3.5). After pressure-cooking in buffer
for 5 minutes at full pressure, sections were left to stand for 20 minutes before cooling
under running tap water. The optimal preparation of the slides was therefore
established for each primary antibody investigated. In general, staining for antigens
expressed within the nucleus required this procedure, whereas the expression of
cytoplasmic and peri-membranous antigens, such as growth factor receptors, did not.
Endogenous peroxidase activity was blocked by immersing all sections in 3% (v/v)
H2O2 in methanol (both from BDH Laboratory Supplies, Poole, Dorset, UK) for 30
minutes. After washing in water, the slides were transferred into Tris-buffered saline
(TBS: 0.05M Tris-HCl, 0.85% NaCl, pH 7.4) for two 5-minute washes.
To block non-specific binding sites, sections were incubated for 30 minutes with the
appropriate normal serum diluted 1:5 in TBS containing 5% (w/v) bovine serum
albumin (BSA: Sigma, Poole, Dorset, UK). Normal rabbit serum (NRS) was used for
MAGE, Ki67, EGF receptor, the GDNF family of receptors, neurturin, FGF-4 and
PCNA; normal goat serum for FGF receptor and GM-CSF receptor; and normal swine
serum for phosphohistone H3, IGF-1 receptor, Activin receptor, GDNF, LIF receptor,
Oct-4 and C-Kit.
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Immunostaining with certain antibodies, as detailed in Table 3.1, also required
blocking of endogenous biotin using an avidin/biotin blocking kit (Vector
Laboratories Inc., Peterborough, UK). The primary antibodies that required an
avidin/biotin block were either raised in goat, for which an Envision detection system
is not available, or were shown to have improved detection using a biotinylated
secondary antibody as opposed to the appropriate Envision method. The addition of
avidin was incorporated into the BSA block at a dilution of 8 drops per ml, after
which the sections were transferred into TBS for two 5-minute washes. Sections were
then incubated in biotin, at a dilution of 8 drops per ml in TBS, before two further 5-
minute washes in TBS.
Primary antibodies were then added to the sections at the optimal dilution (Table 3.1),
in the appropriate normal serum in 5% TBS/BSA. Because the optimal dilution was
initially not known for each primary antibody, a range of concentrations was applied
to the tissue. The most appropriate antibody concentration was then selected, based
on the intensity of staining and the level of background observed throughout this
range. Following the application ofprimary antibody, sections were incubated
overnight at 4°C in a humidified chamber.
Sections were then washed in TBS. Due to problems encountered with heavy
background staining, sections for immunolocalization ofgrowth factor receptors were
initially washed in TBS containing 0.05% polyoxyethylene sorbitan monolaurate
('Tween'- Sigma, Poole, Dorset, UK) before the second TBS wash. All sections were
then incubated for 30 minutes in the appropriate secondary antibody (Table 3.1),
77
diluted in the same normal serum as the primary antibody. Sections were then
washed twice in TBS, which included an initial wash in TBS with 0.05% Tween for
those sections stained for growth factor receptors. Those sections that had required an
avidin/biotin block were then incubated for 30 minutes with avidin-biotin conjugated
to horseradish peroxidase (HRP) (Vector Laboratories, as above), diluted in 0.05M
Tris-HCl, pH 7.4, according to the manufacturer's instructions. All sections were
then washed twice (5 minutes each) in TBS.
Bound antibody was visualized using 3,3-diaminobenzidine tetrahydrochloride (DAB)
(DAKO) until staining was optimal, at which time the reaction was stopped by
immersing sections in distilled water. All sections were then counterstained with
haematoxylin, dehydrated in graded ethanols, cleared in xylene and coverslipped
using Pertex mounting medium (CellPath pic, Hemel Hempstead, UK).
Negative controls, omitting the primary antisera, were included in each experiment.
Due to limited availability of tissue, these sections were frequently from adult testis
rather than younger ages. However, if this was the case adult sections were also
included within the experiment in order to ensure lack of immunoexpression was due
to omission of primary antibody rather than reflecting the pattern of expression at this
age.
3.4 Immunofluorescence
Immunofluorescence was used for double staining the growth factor receptors with
markers of proliferation. Based on the results from the initial immunohistochemical
studies, the growth factor receptors selected for further investigation were the EGF
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receptor and a member of the GDNF family of receptors, GFR-a2. Co-localisation of
these receptors was attempted with Proliferating Cell Nuclear Antigen (PCNA) as a
marker of proliferation. This was used in addition to both Ki67 and phosphohistone
H3, as these latter antigens require a heat-induced retrieval step, which affected the
quality of staining of the growth factor receptors. Detection ofPCNA does not
require this process, and has been used as a proliferative marker in previous studies on
the marmoset (Kelnar et al, 2002).
Sections were prepared as described previously, with incubation for 30 minutes in
normal rabbit serum prior to the application ofPCNA antibody (Santa Cruz, sc-7907,
rabbit polyclonal) at a dilution of 1:20 in normal swine serum. Following incubation
overnight at 4°C, the sections were washed in TBS as above and PCNA was
visualised by Streptavidin alexa-488 (Molecular Probes Inc., Eugene, OR97402,
USA) via a swine anti-rabbit biotinylated secondary antibody. Antibody to either the
EGF receptor or GFR-a2 was then applied, both at a dilution of 1:75. This optimal
dilution was obtained after testing a range of antibody concentrations. Sections were
incubated overnight at 4°C and following washes in TBS (with 0.05% Tween as
above), the receptors were visualised by a tyramide enhanced Cy5 via mouse
Envision (DAKO) for the EGF receptor and rabbit anti-goat peroxidase (Sigma,
A5420) for the GFR-a2. All sections were then counterstained with propidium iodide
(Sigma, 1:2000 in Phosphate Buffered Saline), and mounted in Permafluor.
For co-localisation with Ki67 or phosphohistone H3, sections were initially subjected
to a heat-induced antigen retrieval step in 0.01M citrate (pH 6.0), as discussed.
Primary antibody was applied following incubation in normal swine serum for 30
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minutes. Because both the EGF receptor antibody and the Ki67 antibody were raised
in mouse, an alternative Ki67 antibody was required. A polyclonal antibody raised in
rabbit (DAKO, A0047) was therefore used, at a dilution of 1:50. The antibody to
Phosphohistone H3 was as before, used at a dilution of 1:300. Following incubation
overnight at 4°C, the sections were then treated as above, with the application of
antibody to either the EGF receptor or GFR-a2.
3.5 Double staining using Fast Blue
Double staining using putative stem cell markers was attempted with confocal
microscopy, but analysis was problematic because of the small number of positive
cells. Therefore double staining using light microscopy was also used. Following
visualisation of the stem cell marker with DAB, sections were prepared for labelling
with antibody to Ki67 as described in section 3.3, although the latter antibody was
used at a dilution of 1:5 overnight to improve detection. Following two 5-minute
washes in TBS, sections were incubated for 30 minutes in anti-mouse alkaline
phosphatase Envision (DAKO). Sections were subsequently washed in TBS (2x5
minutes) and bound antibody was visualized with Fast Blue (Sigma), before mounting
in Permafluor.
3.6 Image Analysis
Non-fluorescent images were photographed using a Provis microscope (Olympus
Optical, London, UK) fitted with a Kodak DCS330 digital camera (Eastman Kodak,
Rochester, NY, USA). Fluorescent images were captured using a Zeiss LSM
Axiovert 100M confocal microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).
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Images were compiled using Photoshop 7.0 (Adobe Systems Inc., Mountain View,
CA, USA) before being printed using a Hewlett-Packard laser jet 4600dn printer.
The immunoexpression ofgrowth factor receptors was initially evaluated in adult
testis, in order to assess the full range ofgerm cells that expressed particular receptors
during normal spermatogenesis. This information, together with the characteristics of
immunopositive cells at 35 weeks of age, enabled better interpretation of receptor
expression prepubertally. It is emphasised that certain conclusions regarding
immunoexpression within marmoset testis are based on qualitative information, rather
than cell quantification as detailed below. The photomicrographs presented are
merely examples in order to illustrate these conclusions. However, where appropriate
cell quantification is used to substantiate this analysis.
3.7 Cell Quantification
Cell counts ofMAGE positive cells and those stained for the proliferative markers,
Ki67 and Phosphohistone H3, were performed at 35 weeks of age, both for control
animals and those treated previously with a GnRH antagonist. Due to wide inter-
animal variability, paired data obtained from control and GnRH antagonist-treated co-
twins («=4) are presented. However, due to the small number of cells labelled with
Phosphohistone H3, analysis of 35 week old singleton animals (controls, n=3; treated,
n=5) was also included, in addition to paired analysis of co-twins.
For analysis of the effect of suppression of the neonatal testosterone surge, cell counts
were also performed for MAGE at 4 weeks of age, both for control animals and those
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treated previously with a GnRH antagonist. As above, paired data from control and
GnRH antagonist-treated co-twins were obtained («=4).
Using a systematic clock-face sampling pattern, selected fields were viewed at 20x
magnification under a light microscope (Zeiss Axiostar plus). Tubules were selected,
also on the basis of a clock-face pattern, and total numbers of stained and unstained
cells per tubule were obtained. From this, a mean ratio of stained to unstained cells
per tubule was calculated for each animal. This approach was chosen in preference to
calculating total cells per testis, because previous studies (Kelnar et al, 2002) have
demonstrated that total germ cell number is reduced in GnRH antagonist-treated
animals, whereas the spermatogonial labelling index is not. Therefore, to avoid being
misled by changes in total germ cell number, calculating the ratio of labelled to
unlabelled cells per tubule allowed a proliferation index to be determined. All
immunopositive cells were noted to be germ cells, with no staining of Sertoli cells.
Quantification ofgerm cells expressing the GFR-a2 receptor was also performed for
both control and GnRH antagonist-treated animals. Sections were examined under
oil-immersion using a Leitz 63x objective fitted to an Olympus BH2 microscope, and
images were analysed using Image Pro-plus version 4.5.1 with Stereology Pro 5.0
(Media Cybernetics). Twenty randomly selected fields were examined and from a
900-point grid, points falling over germ cell nuclei were categorised as either stained
or unstained. These were expressed as a percentage of the total points counted.
Measurement of the mean nuclear diameter for both stained and unstained germ cells,




With regards to MAGE and Ki67 staining, a mean ratio of immunopositive to
immunonegative cells per tubule was calculated for each animal. Each control animal
was compared with its treated co-twin. The means of the control co-twins («=4) and
of the treated co-twins (n=4) are also presented, with an error bar of 1 standard
deviation. With regards to Phosphohistone H3 staining, a mean ratio of
immunopositive to immunonegative germ cells per tubule was calculated for each
animal. Each control animal was compared with its treated co-twin, and means from
each group are presented in a similar manner to the above. However, because
phosphohistone is expressed within a much narrower window, and therefore
significantly fewer cells will be immunopositive than compared to a marker such as
Ki67, data from singleton animals were included in addition. Therefore a mean ratio
of stained to unstained germ cells for both the total control group (n=l) and the total
treated group (n=9) is presented, together with error bars of 1 standard deviation.
Immunostaining for the GFR-a2 receptor is expressed as a ratio of the total stained
germ cells per testis compared to total unstained germ cells per testis. Paired data
from co-twins are presented («=4), together with means from each group and error
bars of one standard deviation.
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Chapter 4
Results- Germ Cell Numbers and Proliferation
4.1 Introduction
The first part of this study aimed to investigate the hypothesis that spermatogonial
proliferation in the prepubertal marmoset is gonadotrophin independent. Kelnar et al
(2002) demonstrated that the proliferation ofgerm cells in this animal model, as
assessed by the PCNA labelling index of spermatogonia, was unaffected by prior
treatment with a GnRH antagonist. If this finding could be confirmed, using other
markers of cell proliferation, this may explain why suppression of the gonadotrophin
axis has not been successful in alleviating the gonadotoxic damage secondary to
cancer treatment.
4.2 Methods
In order to investigate this hypothesis, the immunoexpression ofmarkers ofgerm cell
number and proliferation was studied in the prepubertal marmoset testis. This
expression was then compared to testes from prepubertal animals that had previously
received treatment with a GnRH antagonist.
4,2,1 Animals and Treatments
Animals used for study were 35-week-old marmosets, as detailed in chapter 3.
Because of inter-animal variability, four sets of co-twins were investigated, with one
twin having received GnRH antagonist treatment between 25 and 35 weeks of age,
whilst the other twin acted as a control.
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In addition to investigating the role ofgonadotropins in the regulation of
spermatogonial proliferation during 'infancy', the effects, if any, of the neonatal
testosterone surge on germ cell number and proliferation, based on the
immunoexpression of the same markers, was also studied. Paired analysis of four-
week-old co-twins (n=4) was employed, with one twin having received a GnRH
antagonist since birth, whilst the other twin acted as a control.
As discussed in chapter 3, it was expected that fewer cells would be immunopositive
for phosphohistone as compared to Ki67. In view of this, singleton animals were also
included in the analysis of the immunoexpression of phosphohistone, in order to
improve statistical significance.
4.2.2 Immunohistochemical markers
MAGE-A4, Ki67 and Phosphohistone H3 were used as markers to investigate germ
cell number and proliferation, and to enable comparison of spermatogonial
proliferation in control animals with those treated with a GnRH antagonist.
The melanoma-associated antigen (MAGE) is expressed both within the normal testis
and in certain testicular neoplasms (Aubry et al, 2001). Positive immunostaining for
MAGE-A4 has been demonstrated in gonocytes and spermatogonia, with weak
staining in spermatocytes. Spermatids, Sertoli and Leydig cells are all
immunonegative (Yakirevich et al, 2003). It therefore represents a useful marker for
the detection and quantification of spermatogonial, and earlier, germ cell types.
85
Ki67 is a nuclear antigen expressed in all phases of the cell cycle, except Go and early
Gi (Gerdes etal, 1984), and has been widely used as an immunohistochemical marker
of cellular proliferation. Phosphorylated Phosphohistone H3 is expressed in cells
from prophase to telophase (Juan et al, 1998), and thus represents a marker ofmitosis.
This latter marker is more specific than Ki67 as it will not detect cells undergoing
DNA repair, but as considerably fewer cells will be immunopositive for
Phosphohistone H3 than for Ki67, both antibodies were used in this study in order to
increase statistical power.
4.2.3 Immunohistochemistrv
The detection of these antigens within marmoset testis was performed as described in
section 3.3. Mouse Envision (DAKO) was used for the detection of both MAGE and
Ki67, whilst rabbit Envision (DAKO) was used for Phosphohistone H3. Both Ki67
and Phosphohistone H3 required a heat-induced antigen retrieval step prior to
detection.
4.2.4 Cell Quantification
The quantification of immunopositive cells, as detailed in section 3.7, enabled a ratio
of stained to unstained cells per seminiferous tubule cross-section to be calculated for
each animal investigated. These ratios were compared between control and treated
co-twins. Results are presented graphically, with original data tabulated in appendix
A. Assessing the proportion of stained to unstained cells per tubule in this manner
allows the determination of the proliferation index of germ cells within each animal.
This method is chosen in preference to calculating germ cell number per testis, as the
latter would be indicative ofboth germ cell proliferation and survival. As discussed
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in section 3.7, previous studies (Kelnar et al, 2002) have demonstrated that germ cell
survival is affected by GnRH antagonist treatment, presumably via effects on Sertoli
cell function. In the context of this thesis, assessment ofgerm cell proliferation is the
primary aim, as it is this that will render the germ cells susceptible to cytotoxic
therapies.
4.3 Results
The immunoexpression ofMAGE, a germ cell marker, in 35-week-old co-twins is
illustrated in Figure 4.1. Numerous cells with stained nuclei were observed in the
testes of prepubertal control animals, and this was unaffected by previous treatment
with a GnRH antagonist. Enumeration of immunopositive cells per seminiferous
tubule showed no significant difference between control and treated co-twins (Figure
4.2). It is important to note that GnRH antagonist treatment has been demonstrated to
cause a reduction in mean testis weight by 34% (Kelnar et al, 2002), and thus total
germ cell numbers within the testes may have been reduced.
Figure 4.3 illustrates the immunoexpression ofMAGE at 4 weeks of age, in testes
from both a control animal and its co-twin, the latter having received treatment with a
GnRH antagonist since shortly after birth. Suppression of the neonatal testosterone
surge did not affect the testicular expression of this antigen, and enumeration of
immunopositive cells per seminiferous tubule showed no significant difference
between control and treated co-twins (Fig 4.4).
Immunoexpression of the proliferation markers, Ki67 and Phosphohistone H3, within
the testes from 35-week-old animals, is demonstrated in Figures 4.5 and 4.6. As
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Figure 4.1 Immunoexpression of MAGE in marmoset co-twins at 35 weeks of age
(a) control animal (b) animal treated with GnRH antagonist (c) negative control
(a) Immunoexpression of
MAGE in testis from a 35
week old control animal. The
numerous stained nuclei




MAGE in testis from the 35
week old co-twin of the above
animal, which has received
prior treatment with a GnRH
antagonist. The numerous
stained nuclei represent germ
cells within the seminiferous * *
tubules (lOx magnification).
(c) Section of testis from a 35
week old animal, which has
been treated identically to the
above sections other than the
omission of the primary
antibody, in order to act as a
negative immunohistochemical
control (lOx magnification).
No expression is observed, in

































































Figure 4.3 Immunoexpression ofMAGE in marmoset co-twins at 4 weeks of age
(a) control animal (b) animal treated with GnRH antagonist fc) negative control
(a) Immunoexpression of -
MAGE in testis from a 4 week ^ V
old control animal. The stained * •
nuclei represent germ cells •
within the seminiferous tubules . t « •
(20x magnification).
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MAGE in testis from the 4
week old co-twin of the above
animal, which has received
treatment since shortly after
birth with a GnRH antagonist.
The stained nuclei represent
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(c) Section of testis from a 4
week old animal, which has
been treated identically to the
above sections other than the
omission of the primary
antibody, in order to act as a
negative immunohistochemical
control (20x magnification).
No expression is observed, in
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Figure 4.5 Immunoexpression of Ki67 in marmoset co-twins at 35 weeks of age
(a) control animal (b) animal treated with GnRH antagonist (c) negative control
(a) Immunoexpression ofKi67
in testis from a 35 week old
control animal. The stained
nuclei represent proliferating
cells within the tissue, and
were identified as germ cells
(lOx magnification).
(b) Immunoexpression ofKi67
in testis from the 35 week old
co-twin of the above animal,
which has received prior
treatment with a GnRH
antagonist. The stained nuclei
represent proliferating cells
within the tissue, and were
identified as germ cells (lOx
magnification).
(c) Section of testis from a 35
week old animal, which has been
treated identically to the above
sections other than the omission
of the primary antibody, in order
to act as a negative
immunohistochemical control
(1Ox magnification). No
expression is observed, in
contrast to the above sections.
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Figure 4.6 Immunoexpression of Phosphohistone H3 in marmoset co-twins at 35
weeks of age (a) control animal (b) animal treated with GnRH antagonist
(a) Immunoexpression of
Phosphohistone H3 in testis
from a 35 week old control
animal (lOx magnification).
The stained nuclei (arrowed)
represent proliferating cells
within the tissue, and were
identified as germ cells (below-
lOOx magnification). > - v<
'if-
(b) Immunoexpression of
Phosphohistone H3 in testis
from the 35 week old co-twin
of the above animal, which has




proliferating cells within the
tissue, and were identified as
germ cells (below- lOOx
magnification). r ysSft&mS1
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expected, fewer cells exhibited immunostaining for Phosphohistone H3 than for Ki67,
due to the narrower window of expression of the former antigen. Staining for both
Ki67 and Phosphohistone H3 was within the nucleus of the cell, and all positive cells
were identified as germ cells, with no Sertoli cells demonstrating proliferation at this
age. As with expression of the MAGE antigen, the numbers ofpositive cells per
seminiferous tubule cross-section were not significantly different between control and
treated animals (Figures 4.7 and 4.8).
Figures 4.9 and 4.10 demonstrate the immunoexpression of these proliferation
markers within the testes at 4 weeks of age. Similar to the situation at 35 weeks of
age, fewer cells exhibited immunostaining for Phosphohistone H3 than for Ki67. The
expression of these antigens did not appear to be affected by suppression of the
neonatal testosterone surge. However, because Sertoli cells are still proliferating
during the neonatal period (Sharpe et al, 2003a), enumeration of immunopositive cells
would not be a reliable indicator ofgerm cell proliferation, and was therefore not
performed at this age.
4.4 Discussion
This part of the study aimed to investigate the hypothesis that prepubertal germ cell
proliferation in the marmoset is gonadotrophin independent.
Kelnar et al (2002) demonstrated that the rate ofproliferation of spermatogonia in the
35-week-old marmoset, based on the immunoexpression ofPCNA, was not affected
by prior administration of a GnRH antagonist. Here we have shown that germ cell













































































































































































































Figure 4.9 Immunoexpression of Ki67 in marmoset co-twins at 4 weeks of age
fa) control animal fb) animal treated with GnRH antagonist
(a) Immunoexpression ofKi67
in testis from a 4 week old
„ %
control animal. The stained - •
.
nuclei represent proliferating ;
- ---
include Sertoli cells as well as -
» A- ^ ■
cells within the tissue, and will




in testis from the 4 week old
co-twin of the above animal,
which has received treatment
. *
since shortly after birth with a
GnRH antagonist. The stained _
ni ir'loi rftnr^cont nrAliforafinnrnuclei represent proliferating
cells within the tissue, and will
include Sertoli cells as well as . _
germ cells (20x magnification).
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Figure 4.10 Immunoexpression ofPhosphohistone H3 in marmoset co-twins at 4
weeks of age (a) control animal lb) animal treated with GnRH antagonist
(a) Immunoexpression of
Phosphohistone H3 in testis
from a 4 week old control
animal (20x magnification).
The stained nuclei (arrowed)
represent proliferating cells
within the tissue, and may
include Sertoli cells as well as




Phosphohistone H3 in testis
from the 4 week old co-twin of
the above animal, which has
received treatment since shortly
after birth with a GnRH
antagonist (20x magnification).
The stained nuclei (arrowed)
represent proliferating cells
within the tissue, and may
include Sertoli cells as well as
germ cells (below- lOOx
magnification).
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and Phosphohistone H3, is indeed gonadotrophin independent at this age. It is
reiterated that the tissue used within this study was identical to that used by Kelnar et
al (2002), and therefore this work should ideally be repeated using alternative
animals. However, the availability of suitable primate tissue restricts the opportunity
for this to occur.
In addition to the above markers of proliferation we have demonstrated that, using
immunoexpression ofMAGE, the number ofgerm cells present within the
seminiferous tubule, as a proportion of the total cells present, is unaffected by prior
administration ofGnRH antagonist. These results would suggest that spermatogonial
proliferation in the prepubertal marmoset is undoubtedly gonadotrophin independent.
Despite the hypothalamic-pituitary-gonadal axis being relatively 'quiescent' during
this period of testicular development, administration of a GnRH antagonist to the
prepubertal marmoset between 25 and 35 weeks of age does have a detectable effect
on testicular morphology and function (Kelnar et al, 2002). Mean testis weight is
reduced by 34% and functional maturation ofboth Sertoli cells and Leydig cells is
impaired. The total number ofgerm cells, including proliferating germ cells, will be
reduced in the treated animals (Kelnar et al, 2002). However, germ cell proliferation
per se appears unaffected by prior treatment with a GnRH antagonist. It appears that,
although spermatogonial proliferation is unaffected by this treatment, fewer of these
cells survive. This is presumably because they do not receive the appropriate
metabolic support from the Sertoli cells, as these cells have been deprived of the
hormonal stimuli required to express these functions (Kelnar et al, 2002).
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Similarly, suppression of the neonatal testosterone surge does not appear to affect
spermatogonial proliferation during this period of testicular development. Analysis of
the immunoexpression of proliferation markers at 4 weeks of age is complicated by
Sertoli cell replication at this age, and thus not all proliferating cells present within the
seminiferous tubules are germ cells. However, this conclusion supports previous data
also suggesting that spermatogonial proliferation in the neonatal period is
gonadotrophin independent (Sharpe et al, 2003b). This latter study demonstrated that
germ cell proliferation and differentiation was unaffected by suppression of the
neonatal testosterone surge, although as with animals suppressed during 'infancy',
there was impaired germ cell survival due to withdrawal of gonadotrophin support for
Sertoli cells.
Suppression of the hypothalamic-pituitary-gonadal axis in adult rodents receiving
chemotherapy and radiotherapy results in an improved recovery of spermatogenesis
following the gonadotoxic insult (Ward et al, 1990; Kurdoglu et al, 1994). The
mechanism of testicular damage following cytotoxic therapy is uncertain but appears
to involve depletion of the proliferating germ cell pool, by killing cells not only at the
stage of differentiating spermatogonia (Meistrich et al, 1982), but also stem cells
themselves (Bucci and Meistrich, 1987). It is presumed that gonadotrophin
suppression during cytotoxic therapy inhibits germ cell proliferation and thus reduces
their susceptibility to such insults. However, as discussed previously, the precise
mechanism of fertility protection in this manner remains uncertain, as it has also been
demonstrated that hormonal manipulation with a GnRH antagonist results in
successful recovery of spermatogenesis in rats even when given after the gonadotoxic
insult (Meistrich and Kangasniemi, 1997).
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Despite the success of these techniques in rodent models, trials of hormonal
manipulation to protect testicular function in both primate models (Kamischke et al,
2003) and clinical studies (Thomson et al, 2002b) have failed to demonstrate any
benefit, regardless of the timing ofgonadotroph^ suppression in relation to the
cytotoxic insult. Although the severity of the gonadotoxic insult and the uncertainty
regarding the mechanism of gonadal protection complicate interpretation of these
studies, it is clear that a better understanding of spermatogenesis in the primate is
needed before further clinical trials in this area. As discussed previously, significant
differences exist between the organisation of spermatogenesis in rodents as compared
to a number of primate species, including man, which complicates the extrapolation of
data from rodent models. Our results using the marmoset as a primate model strongly
suggest that prepubertal spermatogonia! proliferation in this species is gonadotrophin
independent, and, should the same hold true for the human, this probably explains the
failure ofgonadal protection based on the hypothalamic-pituitary-gonadal axis.
The identification of factors that do regulate spermatogonial proliferation would not
only improve our understanding of the physiology of the developing primate testis,
but may also aid in devising strategies to protect fertility in boys treated for cancer.
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Chapter 5
Results- Growth Factor Receptors and Associated Ligands
5.1 Introduction
Having established that spermatogonial proliferation in the prepubertal marmoset
testis is gonadotrophin independent, the next phase of the study was directed towards
elucidating what factors might regulate their proliferation at this age. If these factors
could be identified, firstly in this animal model and subsequently in the human testis,
they would represent novel targets for gonadal protection in prepubertal boys
receiving gonadotoxic cancer therapy.
As mentioned previously, a number of growth factors have been identified within
rodent testes. A number of these factors have been implicated as having a role in the
regulation of spermatogonial proliferation, predominantly on the basis ofgene
knockout models and studies of spermatogonia cultured in vitro. Despite the
recognised differences between spermatogenesis in rodents and marmosets, these
growth factors were used as a starting point for investigation.
5.2 Methods
To identify which growth factors may be involved in the regulation ofgerm cell
proliferation in the prepubertal marmoset, their immunoexpression within the testis
was investigated. In particular, the immunoexpression of their associated receptors in
spermatogonia was determined.
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Following the identification ofpotentially relevant growth factor receptors, the
intention was then to co-localise these receptors with markers of cell proliferation, in
order to ascertain their relationship with actively proliferating spermatogonia.
5.2.1 Animals and Treatments
Sections of testis taken from marmosets killed at 35 weeks of age were studied. To
put findings from these animals into context, testes from animals killed at various
time points, from the neonatal period through to adulthood, were also investigated. In
addition, the immunoexpression of these growth factors and their receptors was
studied in animals that had previously received treatment with a GnRH antagonist, as
detailed in chapter 3. This included 35-week-old animals that had been treated with a
GnRH antagonist between 25 and 35 weeks of age, and animals at 4 weeks of age in
which the neonatal testosterone surge had been suppressed by such treatment.
Analysis of testes from these animals would establish the gonadotrophin dependence
of growth factors identified.
5.2.2 Immunohistochemical Markers
Immunohistochemical markers studied were selected on the basis of rodent studies
(Tajima et al, 1995; Dirami et al, 1999; Wahab-Wahlgren et al, 2003; Kanatsu-
Shinohara et al, 2003). Those studied were Insulin-like Growth Factor-1 (IGF-1),
Epidermal Growth Factor (EGF), members of the Glial Cell-line Derived
Neurotrophic Factor (GDNF) family, Leukaemia Inhibitory Factor (LIF), Fibroblast
Growth Factor (FGF) and Granulocyte Macrophage-Colony Stimulating Factor (GM-
CSF).
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In order to clarify certain aspects of immunoexpression of these receptors, studies
were also included to investigate the presence of the associated ligands within the
marmoset testis. Those that required further investigation were the GDNF family of
growth factors, because cross-reactivity is reported to occur between family members
(Wang et al, 2000), and the FGF family, in which many members signal via the same
receptor (Bellosta et al, 2001). Thus, with regards to the GDNF family, the
immunoexpression of both GDNF itself and Neurturin was studied. FGF-4 is the
member of the FGF family that has been previously reported to be involved in
spermatogenesis (Yamamoto et al, 2002), and therefore the immunoexpression of this
ligand was also studied.
Activin is a member of the transforming growth factor-P family, which also includes
inhibin, and is involved in the regulation ofFSH secretion (de Kretser et al, 2001).
However, in vitro cultures of rat germ cells with Sertoli cells have suggested that
activin may also act to stimulate spermatogonial proliferation (Mather et al, 1990).
The immunoexpression of the activin receptor in prepubertal marmoset testis was
therefore also included in this study.
5.2.3 Immunohistochemistrv
The immunohistochemical methods used for detecting the presence of these growth
factor receptors and their associated ligands are detailed in chapter 3. Trials under
differing conditions established the optimal method of detection for each primary
antibody studied. As discussed previously, background staining was particularly
problematic in the study of a number of these growth factor receptors in marmoset
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testis, and therefore a variety of techniques were employed to reduce this, such as
washing with TBS containing Tween.
On the basis of these immunohistochemical studies, growth factors potentially
involved in regulating spermatogonial proliferation were selected for further
investigation. Using immunofluorescence, the expression of the growth factor
receptors was co-localised with markers of cell proliferation. Ki67 and
Phosphohistone H3 were initially used, as these had previously been investigated in
marmoset testis. However, because the heat-induced antigen retrieval step required
for the detection of both of these antigens interfered with the detection of the growth
factor receptors, PCNA was predominantly used as a proliferation marker for these
studies.
Immunofluorescence requires more sensitive detection methods than does
conventional immunohistochemistry, and therefore the problem ofbackground
staining was exacerbated.
5.3 Results
In order to aid interpretation of the expression of growth factor receptors
prepubertally, immunopositive cells were initially evaluated in the adult testis, as
discussed in section 3.6.
5.3,1 Immunoexpression ofEGF Receptor
The EGF receptor was localized to the cytoplasm of a number ofgerm cells.
Examination of its expression within the adult testis revealed intense labelling ofB-
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Figure 5.1 Immunoexpression of the EGF Receptor in marmoset testis
(a-c) Adult (d) 35-week-old infant (e) 35-week-oid co-twin treated prepubertallv
with a GnRH antagonist (fl 7-week-old neonate (g) Negative control
(a) Immunoexpression of the
EGF receptor in adult testis.
Intense staining of
spermatogonia is demonstrated
(solid arrows), along with less
intense staining of spermatocytes v„:,.£|
(thin arrows). Occasional germ
cells are immunonegative for the
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immunoexpression of the EGF
receptor in spermatocytes within
adult marmoset testis (lOOx
magnification).
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(d) Immunoexpression of the
EGF receptor in testis from a 35
week old control animal (20x
magnification). Numerous germ
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(e) Immunoexpression of the
EGF receptor in testis from the
35 week old co-twin of the above
animal, which has received prior
treatment with a GnRH
antagonist (20x magnification).
A similar pattern of expression
exists, with both immunopositive
(solid arrows, and demonstrated
below at lOOx magnification) and
immunonegative (arrowheads)
germ cells.
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(f) Immunoexpression of the
EGF receptor in testis from a 7
week old control animal. A
number ofgerm cells are
immunopositive for this receptor
(such as those indicated with
solid arrows), although less so
than at 35 weeks of age. In
addition, they appear to be in a
more central position within the
tubule. Many germ cells are
immunonegative (such as those
indicated with arrowheads) (20x
magnification).
(g) Section of testis from an adult
animal, which has been treated
.. *11 ,
identically to the above sections
other than the omission of the
primary antibody, in order to
a negative immunohistochemical
control (lOx magnification)
expression is observed, in contrast
to the above sections
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spermatogonia (Fig 5.1a, b). Staining of preleptotene and leptotene spermatocytes
was also noted (Fig 5.1a, c), but was of reduced intensity. In addition to staining of
B-spermatogonia, occasional staining ofA-spermatogonia was also demonstrated.
Examination of testes from the 35-week-old animals demonstrated immunoexpression
of this receptor in numerous germ cells within this age group (Fig 5. Id). However,
within the same tubule, a number ofgerm cells were identified that were immuno-
negative for this receptor. A similar pattern of expression was found in animals
treated with a GnRH antagonist (Fig 5. le). The staining for the EGF receptor
observed in testes from the treated animals actually appeared to be more intense,
when compared to control testes, although this finding was not consistent in all
animals studied.
Based on the immunopositive cells observed in the adult, and the characteristics of the
labelled cells seen, including nuclear morphology and cell size, B-spermatogonia
appeared to be the predominant germ cell type that immunostained for the EGF
receptor prepubertally.
Examination of testes from animals killed in the neonatal period demonstrated
immunopositive germ cells, which also appear to be B-spermatogonia (Fig 5. If).
Labelled cells were less numerous than during infancy, and their position within the
seminiferous tubule was noted to be more central as compared to testes from older
animals.
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Indeed, the position of labelled cells within the seminiferous tubules varied with age,
from being central in the neonatal period to exclusively basal in adulthood. At 35
weeks of age labelled cells were noted both centrally and on the basement membrane.
As discussed previously, gonocytes migrate towards the basement membrane during
prenatal and neonatal life. However, at 35 weeks of age tight junctions are forming
between adjacent Sertoli cells, and thus the presence of numerous germ cells in a
central position is unexpected.
Quantification of immunopositive and immunonegative germ cells was not performed
for the EGF receptor due to the wide window of expression, both across different ages
and throughout different cell types. This is in contrast the immunoexpression of
GFR-a2, as discussed below.
No immunoexpression is observed within the negative control slide (Fig 5. lg), which
was treated identically to the other slides except for the omission of the primary
antibody. As discussed in chapter 3, an adult marmoset section was used due to the
availability of tissue.
5,3.2 Immunoexpression ofGFR-a2
As with the EGF receptor, GFR-a2 immunoexpression was localized to germ cell
cytoplasm. Examination of its expression within the adult testis revealed intense
labelling ofB-spermatogonia (Fig 5.2a). However, unlike staining for the EGF
receptor, staining ofgerm cells at more advanced stages of maturation was not found.
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Figure 5.2 Immunoexpression of the GFR-a2 receptor in marmoset testis
fa) Adult fb) 35-week-old infant fc) 35-week-old co-twin treated prepubertally
with a GnRH antagonist fd) 7-week-old neonate (e) Negative control
(a) Immunoexpression ofGFR-
ct2 in adult testis (lOx
magnification). Intense staining
ofB-spermatogonia is
demonstrated (solid arrows, and
mw$m
(b) Immunoexpression ofGFR-
a2 in testis from a 35 week old
control animal (20x
magnification). Numerous germ
cells are immunopositive for this
receptor (such as those indicated
with solid arrows, and shown
below at lOOx magnification),




a2 in testis from the 35 week old
co-twin of the above animal (20x
magnification), which has
received prior treatment with a
GnRH antagonist. A similar
pattern ofexpression exists, with
both immunopositive (solid
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other than the omission of the




expression is observed, in
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Examination of testes from the 35-week-old animals demonstrated immunoexpression
ofGFR-a2 in a significant proportion ofgerm cells within this age group (Fig 5.2b).
Expression of this receptor appeared to be unaffected by previous treatment with a
GnRH antagonist (Fig 5 .2c). Indeed, the proportion of total germ cells stained for
GFR-a2 in control and treated testes was comparable, as demonstrated in Figure 5.3
(data tabulated in appendix B). Based on the pattern of expression in the adult, and
both nuclear morphology and cell size, the germ cells expressing this receptor were
predominantly B spermatogonia.
Examination of testes from animals killed in the neonatal period demonstrated no
expression ofGFR-a2 within seminiferous tubules (Figure 5.2d). Indeed, the only
positive immunoexpression at this age was observed in the interstitium.
No immunoexpression is observed within the negative control slide (Fig 5.2e), which
was treated identically to the other slides except for the omission of the primary
antibody. As discussed in chapter 3, an adult marmoset section was used due to the
availability of tissue.
Because different members of the GDNF family may interact with the GFR-a2
receptor, the immunoexpression ofboth GDNF and Neurturin was also investigated
within the marmoset testis. Expression of these ligands was noted in a number of
germ cells at 35 weeks of age (Fig 5.4). In addition, GDNF, and to a lesser extent











































































Figure 5.4 Immunocxpression of fa) GPNF and (b) Neurturin within 35-week-
old marmoset testis
(a) Immunoexpression ofGDNF
in testis from a 35 week old
control animal. A number of
germ cells are immunopositive
for this ligand (solid arrows), as
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(b) Immunoexpression of
Neurturin in testis from a 35
week old control animal. A
number ofgerm cells are
immunopositive for this ligand
(solid arrows), as well as
occasional Sertoli cells (such as
that indicated by arrowhead)
(20x magnification).
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Figure 5.5 Immunoexpression of GDNF within (a) 7-week-old marmoset testis
and (b) Adult marmoset testis
(a) Immunoexpression of
GDNF in testis from a 7 week
old cormoUnirnal. Numerous -
germ cells are .mmunoposmve V -
for this hgand (solid arrows), • 4^ -
although a number remain
immunonegative (arrowheads)
Unlike lmmunostainmg for the
GFR-c^ receptor at this age,no^jg^p;:#- V
staining is observed within the %#|t|
interstitium (20x
magmfication). feS>8fc3#''IBfeF: "*
a,. gBwWgSligaSwiMC IK -
(b) Immunoexpression of
GDNF in testis from an adult
control animal. As with the
immunoexpression of the GFR
a2 receptor at this age, intense
staining of occasional B-
spermatogonia can be
visualised (solid arrows). The
staining observed within the
lumen of occasional tubules
most likely represents staining
of spermatid cytoplasm, which




Figure 5.6 Immunoexpression ofNeurturin within (a) 7-week-old marmoset
testis and tb) Adult marmoset testis
(a) Immunoexpression of
Neurturin in testis from a 7
week old control animal.
Numerous germ cells are
immunopositive for this ligand
(solid arrows), although a
number remain
immunonegative (arrowheads).
In addition, staining is
observed within the '
(red asterisk), as noted for the
GFR-a2 receptor at this age
(20x magnification).
(b) Immunoexpression of
Neurturin in testis from an
adult control animal. As with
the immunoexpression of the
GFR-a2 receptor at this age,
intense staining of occasional
B-spermatogonia can be
visualised (solid arrows) (lOx
magnification).
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also observed within the testes at other ages. In the neonatal period
immunoexpression ofboth GDNF and Neurturin is observed in a proportion of the
germ cells (Figures 5.5a and 5.6a). Although there is some interstitial staining for
Neurturin, this is not as widespread as that observed for the GFR-a2 receptor at this
age. However, the pattern of immunostaining for these ligands in adult testes did
reflect that seen with the GFR-a2 receptor at this age (Figures 5.5b and 5.6b).
5,3.3 Other Growth Factor Receptors
The prominent immunoexpression in prepubertal germ cells of the receptors discussed
above was not observed with other growth factor receptors investigated.
Prepubertally, very few germ cells expressed the IGF-1 receptor (Fig 5.7a), although
problems with background staining prevented definitive interpretation of this result.
Immunoexpression of the FGF receptor was noted in both germ cells and Sertoli cells
at 35 weeks of age (Fig 5.7b), although artefactual staining was also present and thus
reliable conclusions could not be drawn. However, expression ofFGF-4 was also
noted in both germ cells and Sertoli cells at this age (Fig 5.7c), which would correlate
with these findings. Immunoexpression of the GM-CSF receptor was not observed at
all within the testes at any age (Fig 5 .7d), although the specificity of the antibody used
was uncertain as marmoset thymus, used as a positive control, was also negative.
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Figure 5.7 Immunoexpression within 35-week-old marmoset testis of fa) IGF-1
receptor lb) FGF receptor (c) FGF-4 ligand (d) GM-CSF receptor
(a) Immunoexpression of the ; ^ . f f - ? '
IGF-1 receptor in testis from a 35 ^^HST
week old control animal.
Occasional germ cells are
immunopositive for this receptor
(solid arrows), although
background staining in the
majority of sections analysed
prevented definitive analysis
(20x magnification).
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(b) Immunoexpression of the '
FGF-receptor in testis from a 35
week old control animal. Both
immunopositive germ cells (solid
arrows) and Sertoli cells ...
,
(arrowheads) are noted, although , . -** V>
staimng is not clear and ^ « -*3*.*»•<%- -
conclusions are therefore
difficult to draw (20x
magnification).
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(c) Immunoexpression ofFGF-4
ligand in testis from a 35 week
old control animal. As suggested
with the FGF-receptor,
immunopositive germ cells (solid
arrows) and Sertoli cells
(arrowheads) are noted, although















(d) Immunoexpression of the
GM-CSF receptor in testis from a
Immunoexpression of the LIF receptor was noted in occasional germ cells within the
neonatal period (Fig 5.8a), and this appeared more prominent in testes from animals
that had received previous treatment with a GnRH antagonist (Fig 5.8b). Expression
of this receptor was also observed within interstitial cells. Immunoexpression in germ
cells was not observed beyond early infancy, although the interstitial cell staining
persisted (Fig 5.8c and d).
35 week old control animal. No
staining is observed at all, which
may represent lack of expression
of this receptor in this tissue or a




Figure 5.8 Immunoexpression of the LIF Receptor within the marmoset testis (a)
4-week-old neonate fb) 4-week-old neonate with suppressed neonatal
testosterone surge fc) 35-week-old infant (d) Adult
(a) Immunoexpression of the LIF
receptor in testis from a 4 week
old control animal. Occasional
germ cells are immunopositive
for this receptor (solid arrows).
Staining is also noted within the
interstitium (20x magnification).
(b) Immunoexpression of the LIF
receptor in testis from the 4 week
old co-twin of the above animal,
which has received treatment
with a GnRH antagonist since
shortly after birth. Several germ
cells are immunopositive for this
receptor (solid arrows), and this
appears more pronounced than
that in the control animal (20x
magnification).
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(c) Immunoexpression of the LIF
receptor in testis from a 35 week
old control animal. Although
interstitial staining is noted, there
are no immunopositive cells
within the seminiferous tubule
(20x magnification).
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(d) Immunoexpression of the LIF
receptor in testis from an adult
control animal. In a similar
pattern to that observed at 35
weeks of age, interstitial staining
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5.3.4 Activin Receptor
The activin receptor HA was localised to both the nucleus and cytoplasm ofgerm
cells. At 35 weeks of age, the majority ofgerm cells within the testis express this
receptor, and this pattern is unaffected by previous treatment with a GnRH antagonist
(Fig 5.9).
5.3.5 Confocal Microscopy
From the growth factor receptors studied, the EGF and the GFR-a2 receptors were
investigated further as both were localized to a proportion ofgerm cells prepubertally.
It was hypothesised that the population ofgerm cells expressing the EGF or GFR-a2
receptors would be those that were actively proliferating. However, the opposite was
found, as PCNA immunopositive germ cells did not co-express either growth factor
receptor (Fig 5.10). This pattern of expression was unaffected by previous treatment
with a GnRH antagonist.
With regard to the EGF receptor, which is widely expressed outside of the prepubertal
phase of development, germ cells expressing this receptor were also negative for
PCNA within the neonatal period (Fig 5.11a). However, during adulthood, some
germ cells expressing the EGF receptor were PCNA positive (Fig 5.1 lb).
Confocal microscopy for these two growth factor receptors was also attempted in
combination with either Ki67 or Phosphohistone H3. However, as mentioned
previously, the heat-induced antigen retrieval step required for the detection of these
proliferation markers affects the quality of detection of the cytoplasmic growth factor
receptors. Despite this, the actively proliferating cells still appeared to be separate
from the population ofgerm cells expressing either growth factor receptor (Fig 5.12).
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Figure 5.9 Immunoexpression of the Activin Receptor HA in marmoset testis
(a) 35-week-old infant th) 35-week-old co-twin treated prepubertailv with a
GnRH antagonist (c) Negative control slide
(a) Immunoexpression of the
activin receptor IIA in testis
from a 35 week old control
animal. A large proportion of
germ cells are immunopositive
for this receptor (20x
magnification).
(b) Immunoexpression of the
activin receptor IIA in testis
from the 35 week old co-twin
of the above animal, which has
received prior treatment with a
GnRH antagonist. A similar
pattern of expression exists,
with a large proportion of
immunopositive germ cells
observed (20x magnification).
(c) Section of testis from a 13
week old control animal, which v. , v , ,
has been treated identically to .
the above sections other than V ik" £
the omission of the primary '
antibody, in order to act as a V
negative immunohistochemical """ ' "V K-'
control (20x magnification). ' ^ ' *
No expression is observed,
whereas sections at this age
with primary antibody included *"fc •' ,>.h&
were positive. * a 'k, '* 'WSSHffljf!
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Figure 5.10 Localisation of the proliferation marker PCNA (green) in the 35-
week-old marmoset testis with either, (a) the EGF receptor (blue) or tbt GFR-a2
(blue) using confocal microscopy
(a) Immunoexpression of
PCNA (green) and the EGF
receptor (blue) in testis from a
35 week old control animal,
using confocal microscopy.
PCNA is localised to the
nucleus ofproliferating cells
(indicated by arrowheads). The
EGF receptor is expressed in
the cytoplasm of a proportion
ofgerm cells (solid arrows).
There is no evidence of co-
localisation of these antigens,
in that no cell expresses both
antigens at the same time.
(b) Immunoexpression of
PCNA (green) and the GFR-a2
receptor (blue) in testis from a
35 week old control animal,
using confocal microscopy.
PCNA is localised to the
nucleus ofproliferating cells
(indicated by arrowheads). The
GFR-a2 receptor is expressed
in the cytoplasm of a
proportion ofgerm cells (solid
arrows). As with the pattern of
expression of the EGF receptor,
there is no evidence of co-
localisation of these antigens,
in that no cell expresses both
antigens at the same time.
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Figure 5.11 Localisation of the proliferation marker PCNA (green) with the EGF
receptor (blue) in the marmoset testis using confocal microscopy (a) 7 week old
(b) adult
(red staining represents counterstain with propidium iodide)
(a) Immunoexpression of
PCNA (green) and the EGF
receptor (blue) in testis from a
7 week old control animal,
using confocal microscopy.
PCNA is localised to the
nucleus ofproliferating cells
(indicated by arrowheads). The
EGF receptor is expressed in
the cytoplasm of a proportion
ofgerm cells (solid arrows).
As with immunoexpression of
these antigens at 35 weeks of
age, there is no evidence of co-
localisation of these antigens,
in that no cell expresses both
antigens at the same time.
(b) Immunoexpression ofPCNA
(green) and the EGF receptor
(blue) in testis from an adult
control animal, using confocal
microscopy. As before, PCNA is
localised to the nucleus of
proliferating cells and the EGF
receptor is expressed in the
cytoplasm of a proportion of
germ cells. However, unlike at
earlier ages, occasional germ
cells expressing the EGF recepto
are actively proliferating
(indicated by solid arrows).
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Figure 5.12 Localisation of further proliferation markers (green) in the 35-week-
old marmoset testis with the growth factor receptors (blue) using confocal
microscopy, la) Phosphohistone H3 and the EGF receptor (b) Phosphohistone
H3 and GFR-a2 (c) Ki67 and GFR-q2
(a) Immunoexpression of
Phosphohistone H3 (green) and
the EGF receptor (blue) in testis
from a 35 week old control
animal, using confocal
microscopy. Phosphohistone ED
is localised to the nucleus of a
proliferating cell within the field
(indicated by arrowhead). As
before, the EGF receptor is
expressed in the cytoplasm of a
proportion ofgerm cells (solid
arrows). However, the quality of
immunostaining for the EGF
receptor is impaired due to the
antigen retrieval process.
Despite this, it appears that these
antigens are not co-localised.
(b) Immunoexpression of
Phosphohistone H3 (green) and
the GFR-a2 receptor (blue) in
testis from a 35 week old control
animal, using confocal
microscopy. Phosphohistone H3
is localised to the nucleus of a
proliferating cell within the field
(indicated by arrowhead). As
before, the GFR-a2 receptor is
expressed in the cytoplasm of a
proportion ofgerm cells (solid
arrows). However, the quality of
immunostaining for the GFR-a2
receptor is impaired due to the
antigen retrieval process.
Despite this, it appears that these
antigens are not co-localised.
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(c) Immunoexpression ofKi67
(green) and the GFR-a2 receptor
(blue) in testis from a 35 week
old control animal, using
confocal microscopy. Ki67 is
localised to the nucleus of
proliferating cells (indicated by
arrowheads). As before, the
GFR-a2 receptor is expressed in
the cytoplasm of a proportion of
germ cells (such as that indicated
by the solid arrow). However,
the quality of immunostaining fo
the GFR-a2 receptor is impaired
due to the antigen retrieval
process. Despite this, it appears
that these antigens are not co-
localised.
5.4 Discussion
The aim of this part of the study was to identify factors that potentially act to regulate
spermatogonial proliferation in the prepubertal marmoset testis. Knowledge of this
process would not only improve our understanding of the physiology of
spermatogenesis and testis development, but would also aid in devising strategies to
protect fertility in boys treated for cancer.
This study has identified a number ofgrowth factor receptors that are prominently
expressed by a proportion ofgerm cells, particularly during prepubertal life. The role
these growth factors may have within the testis is uncertain at present, but the
presence of these receptors warrants further investigation.
5.4.1 Epidermal Growth Factor
The EGF receptor is a transmembrane tyrosine kinase receptor (Ushiro and Cohen,
1980) for members of the transforming growth factor family, including EGF and
Transforming Growth Factor-a (TGF-a). This family ofgrowth factors are involved
in cellular proliferation and differentiation in many tissues.
Within the testis, EGF and related ligands have been shown to have a role in the
regulation of embryonic testicular growth in the rat (Levine et al, 2000). In adult
mice, removal of the submandibular gland, the predominant source ofEGF, results in
infertility, which is reversed by EGF administration (Liu et al, 1994). In addition,
proliferation ofboth murine germ stem cells (Kanatsu-Shinohara et al, 2003) and rat
spermatogonia (Wahab-Wahlgren et al, 2003) is stimulated in vitro by culture
medium containing EGF.
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However, overexpression ofEGF in transgenic mice also results in infertility, with
decreased production of spermatids and spermatozoa (Wong et al, 2000). It has
therefore been suggested that EGF is required at a specific concentration to support
spermatogenesis, in particular for progress from meiosis I to meiosis II (Wong et al,
2000). In vitro studies using adult mouse cryptorchid testes lend support to this
theory, in that EGF in a range of concentrations exhibits differential effects on
proliferation and differentiation of type A spermatogonia (Haneji et al, 1991).
Indeed, this latter study suggested EGF results predominantly in inhibition of the
proliferation and differentiation of type A spermatogonia, perhaps by blocking the
action ofFSH. Thus uncertainties persist regarding the precise role ofEGF within the
mammalian testis.
The EGF receptor has been previously localized within the testis in a number of
animal models. In the prepubertal boar testis weak staining of both spermatogonia
and somatic cells has been described (Caussanel et al, 1996). More mature germ cells
demonstrated increased staining intensity in both the prepubertal animal and the adult,
which in the latter was noted particularly during meiosis and spermiogenesis.
Previous studies using primates have localized the EGF receptor to Leydig cells,
Sertoli cells and peritubular cells, but have not demonstrated germ cell staining
(Radhakrishnan and Suarez-Quian, 1992). Foresta and Varotto (1994) investigated
human testicular tissue, obtained via fine needle aspiration from infertile men, and
demonstrated weak immunostaining of the EGF receptor in Sertoli and germ cells.
Interestingly, the intensity of this staining increased in patients with higher FSH
levels.
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The results presented here are the first to demonstrate such prominent
immunostaining of the EGF receptor in prepubertal germ cells in a primate model.
The receptor was localized to a proportion of germ cells, the majority ofwhich were
identified as B spermatogonia. In contrast to previous studies, the receptor was not
detected on somatic cells.
Although, as mentioned previously, the submandibular gland is the predominant
source of circulating EGF in mice, Leydig cells are the principal source ofEGF in the
testis (Yan et al, 1998). It therefore seems likely that local production ofEGF plays a
role in the paracrine regulation of germ cell proliferation. The identification of the
EGF receptor on numerous germ cells supports this hypothesis, although the precise
role ofEGF is yet to be elucidated.
Co-expression of the EGF receptor with markers of proliferation using
immunofluorescence demonstrated that those germ cells expressing this growth factor
receptor were quite separate from the actively proliferating cells. This finding was
unexpected as it was suspected that EGF would stimulate spermatogonial
proliferation. This could suggest that EGF is not involved with the regulation of this
process at all. However, because these populations ofgerm cells appeared quite
distinct, in that no germ cell identified as proliferating was also expressing the EGF
receptor, EGF may actually play an inhibitory role in spermatogonial proliferation
during prepubertal life. This could be via inhibition of intrinsic germ cell
proliferation or, alternatively, may occur secondary to interference of stimulatory
pathways. An inhibitory action ofEGF within the testis has been suggested in rodent
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models, as discussed previously (Wong et al, 2000; Haneji et al, 1991). The results
presented here suggest a similar role in the prepubertal primate testis.
Both FSH and testosterone stimulate the mRNA expression of the EGF receptor in the
perinatal rat testis (Cupp and Skinner, 2001). In addition, EGF secretion is increased
by androgenic stimulation (Cain etal, 1994). Thus the hypothalamic-pituitary-
gonadotrophin axis does influence EGF and its actions. The immunoexpression of the
EGF receptor within 35-week-old marmoset testis presented here appeared to be more
intense in animals treated prepubertally with a GnRH antagonist. As FSH levels will
be low in these animals this would appear to contrast with the above studies.
However, this finding was not consistent amongst all co-twin pairs and was not
quantified; therefore firm conclusions are difficult to draw. Further work is required
to elucidate both the regulation ofEGF and its role within the testis, particularly with
regards to spermatogonial proliferation, and it is hoped that the marmoset model will
yield further information.
5,4,2 Glial Cell Line-Derived Neurotrophic Factor Family
The GFR-a2 receptor is a receptor for members of the GDNF family of neurotrophic
factors, which act to promote the survival ofvarious peripheral and central neurons.
This family consists ofGDNF itself, along with neurturin, persephin and artemin, and
are distant members of the transforming growth factor-p superfamily (Saarma, 2000).
These factors act via a receptor complex consisting of one of four co-receptor
subunits (GFRal-4) as a ligand-binding component, together with a common receptor
tyrosine kinase (RET) as a signalling component (Takahashi, 2001). In general,
GDNF binds to GFR-al, neurturin to GFR-a2, persephin to GFR-a3 and artemin to
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GFR-a4, although some cross-reactivity is felt to occur, at least in vitro (Wang et al,
2000).
In addition to their role within the nervous system, GDNF, and to a lesser extent other
family members, are involved in renal development, particularly with regards to
ureteric budding and branching (Pichel et al, 1996).
Expression of GDNF mRNA has been demonstrated in Sertoli cells (Trupp et al,
1995), suggesting this factor may also be involved within the testis. Using mouse
models, Meng et al (2000) have implicated GDNF as having a role in the regulation
of spermatogenesis. Gene-targeted mice with reduced GDNF demonstrate depletion
of germ stem cell reserves, whereas mice over-expressing this factor have an
accumulation ofundifferentiated spermatogonia, secondary to a differentiation block.
The authors suggest that stem spermatogonia favour differentiation when GDNF
levels are low, and favour self-renewal when levels are high. Over-expression of
neurturin in mice models also affects spermatogenesis, although only transiently and
predominantly affects spermatocytes and spermatids (Meng etal, 2001a).
Expression of both GFR-al and GFR-a2 has been previously demonstrated in
testicular germ cells in the mouse, and GDNF and neurturin are present in Sertoli cells
in this species (Viglietto et al, 2000). These ligands stimulate DNA synthesis in
spermatogonia. In addition, murine spermatogonial stem cells proliferate in culture
medium containing GDNF (Kanatsu-Shinohara etal, 2003).
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Based on these previous studies it seems likely that local production ofGDNF and,
perhaps to a lesser extent, neurturin, have a role in the paracrine regulation of
spermatogonial proliferation and differentiation. The results in the marmoset
presented here support this hypothesis, with prominent immunoexpression of the
GFR-a2 receptor demonstrated in a significant proportion ofgerm cells in the
prepubertal primate testis. However, the expression of this receptor was far less
prominent outside this period of testicular development. In the neonatal period
expression was noted within the interstitium only, and in postpubertal animals the
receptor was localized to a very small number of basal germ cells. Regulation of
germ cell proliferation involving GFR-a2 may therefore be particularly important in
the prepubertal primate but perhaps involves a smaller population ofgerm cells at
other ages. In addition, these results implicate neurturin as having a potentially more
important role than GDNF; although as discussed cross-reactivity of the receptors
does occur.
Indeed, expression of the GFR-al receptor, reported to be the main receptor for
GDNF, was demonstrated at all ages but was limited to a very small number ofgerm
cells, as discussed fully in chapter 6. The cells expressing this receptor could include
germ stem cells themselves, supporting a role for GDNF in the regulation of the fate
of stem spermatogonia, as suggested by Meng et al (2000).
Immunolocalization ofboth GDNF and neurturin detected the presence of these
ligands in Sertoli cells and germ cells in marmoset testes. Production ofGDNF by
Sertoli cells has been previously reported, as discussed above, and is presumed to
represent paracrine involvement of these factors within the testis. However, the
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expression of these ligands on germ cells suggests autocrine regulation may also play
a role.
It has been demonstrated that FSH can stimulate the production ofGDNF from Sertoli
cells, and this in turn increases proliferation ofundifferentiated spermatogonia
(Tadokoro etal, 2002). However, this study involved murine models with testes in
which germ stem cells proliferate but do not differentiate, and are therefore unable to
produce offspring. FSH levels within this model are increased beyond physiological
levels, and the authors postulate that this GDNF/FSH pathway is an important
regulatory mechanism in the recovery from impaired spermatogenesis, rather than in
normal states. Within the study reported here, immunoexpression ofGFR-a2 was
unaffected by prior treatment with a GnRH antagonist, although FSH levels will be
suppressed rather than raised following this treatment.
As with the studies investigating the EGF receptor, attempts to co-localize GFR-a2
with markers ofproliferation suggest that germ cells expressing this growth factor
receptor are quite separate from those that are actively proliferating. This raises the
possibility that the role of the GDNF family in spermatogonial proliferation is
inhibitory, at least in the prepubertal primate. This appears to contrast with the
published data using mouse models discussed above, and again illustrates the
difficulty of comparing rodent and primate models to study spermatogenesis. It is
hoped that further investigation using the marmoset model will shed more light into
the role of these factors.
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5.4.3 Leukaemia Inhibitory Factor
LIF is a member of the interleukin-6 cytokine family and, in addition to effects on the
haematopoietic system, acts to modulate endocrine function in a variety of tissues,
acting via a common LIF receptor (Auernhammer and Melmed, 2000). Within the
reproductive system, LIF plays an important role in blastocyst implantation and the
establishment ofpregnancy (Lass et al, 2001). With regards to the male reproductive
system, the addition ofLIF to cell cultures from the neonatal rat testis results in
enhanced survival of both Sertoli cells and gonocytes (de Miguel et al, 1996). Rather
than an effect on cell proliferation, the mechanism of action is felt to be via
prevention ofapoptosis (Pesce et al, 1993). More recently it has been demonstrated
that LIF also inhibits steroidogenesis in the Leydig cell (Manduit et al, 2001). In
addition, germ stem cells from the mouse proliferate in culture medium containing a
number ofgrowth factors including LIF (Kanatsu-Shinohara et al, 2003).
Therefore, as with other cytokines and growth factors, LIF is likely to act within the
testes in a paracrine or autocrine manner, and perhaps has a particular role in
regulation of the germ cell population during the perinatal period of testicular
development. Peritubular cells appear to be the principal source ofLIF (Piquet-
Pellorce et al, 2000), and using porcine models, the LIF receptor has been
demonstrated on Leydig cells, Sertoli cells and spermatogonia (Manduit et al, 2001).
Using the marmoset model here, immunoexpression of the LIF receptor in Leydig
cells, from the neonatal period through to adulthood, has been demonstrated. With
regards to germ cell staining, prominent expression of this receptor on a number of
germ cells during the neonatal phase of testicular development has been shown.
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However, this does not persist beyond around 18-24 weeks of age. This certainly
supports the hypothesis that LIF acts to regulate the germ cell population during early
life, and further studies are warranted to investigate its precise role. Interestingly,
immunoexpression of the LIF receptor in germ cells appeared more pronounced in
animals that had had their neonatal testosterone surge suppressed by prior
administration of a GnRH antagonist. One could speculate that increased receptor
expression may increase survival of these germ cells via a reduction in apoptosis, and
that this is perhaps a compensatory mechanism of the germ cell, secondary to reduced
Sertoli cell support due to lowered FSH levels.
The lack of expression of the LIF receptor in germ cells from animals at older ages
suggests that this cytokine is perhaps less important in germ cell regulation during the
'infancy' phase of testicular development, and is therefore unlikely to contribute to
the development of a strategy to protect fertility in boys treated for cancer.
5,4,4 Fibroblast Growth Factor
FGF represents a further family ofgrowth factors that have been previously
implicated in the regulation of spermatogenesis within the mammalian testis. This
family consists of 22 ligands, which are known to act via four tyrosine kinase
receptors (Bellosta et al, 2001), and they play key roles in embryonic development.
In adult tissues, FGF members are thought to be involved in angiogenesis and wound
healing. More recently, expression of the gene encoding FGF-4 has been
demonstrated in Sertoli cells of the adult testis, and over-expression of this gene in
transgenic mice results in markedly enhanced spermatogenesis (Yamamoto etal,
2002). Furthermore, these transgenic mice demonstrated improved recovery
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following adriamycin-induced testicular toxicity, although the precise mechanism
underlying this remains uncertain.
FGF receptors have been demonstrated on germ cells and somatic cells of the testes,
both in the immature rat (Cancilla and Risbridger, 1998) and adult men (Steger et al,
1998). In addition, murine stem spermatogonia have been cultured in medium
containing basic FGF (Kanatsu-Shinohara et al, 2003).
Using the marmoset model we detected immunoexpression of the FGF-1 receptor
within the testis, in both germ cells and Sertoli cells, although artefactual staining
affected the interpretation of these results and, as such, conclusions regarding
functional significance are difficult to draw. Investigation ofFGF-4, as a potential
ligand involved in spermatogenesis, detected its presence in both germ cells and
Sertoli cells, correlating with the data obtained from rodent models. Thus members of
the FGF family may play a role in the regulation of spermatogenesis in the primate,
although further investigation is required.
5,4,5 Insulin-like Growth Factor
Similarly, conclusions regarding the role of IGF-1 in the prepubertal primate testis are
difficult to draw based on this immunohistochemical study. This growth factor has a
variety of functions within a number of tissues. With regard to the testes,
differentiation of murine A spermatogonia can be induced by culture medium
containing IGF-1 (Tajima et al, 1995), and IGF-1 has been shown to stimulate DNA
synthesis in rat spermatogonia in vitro (Soder et al, 1992). In addition, studies of
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IGF-1 levels in seminal plasma from infertile men have also implicated this growth
factor as having a role in spermatogenesis (Colombo and Naz, 1999).
Although immunoexpression of the IGF-1 receptor was detected in the prepubertal
marmoset, this was only in a minority ofgerm cells and problems with background
staining affected interpretation of these results. It should be noted, however, that
because only a small number ofgerm cells express a receptor, this does not exclude a
significant role of the corresponding ligand. This is particularly true if those germ
cells with positive expression are actually stem cells, as described in the following
chapter. However, the small number of positive cells does make interpretation and
further analysis more problematic.
5,4,6 Granulocyte Macrophage Colony Stimulating Factor
Immunoexpression of the receptor for GM-CSF was not detected in the marmoset
testis at any age. GM-CSF is a cytokine that stimulates the proliferation and
maturation of haematopoietic cells (Gasson, 1991). However, it is also produced by
testicular macrophages in high concentrations (Kern et al, 1995) and can cross the
blood-testis barrier in mice (McLay et al, 1997). Dirami et al (1999) have
demonstrated an enhanced survival of porcine spermatogonia in culture medium
containing GM-CSF, although the effect of this growth factor on proliferation was not
established. In addition, the authors report localization of the GM-CSF receptor in
type A spermatogonia in the mouse. More recently, the presence of this receptor has
been demonstrated in germ cells from adult men and in bull spermatozoa (Zambrano
et al, 2001). The addition ofGM-CSF to these latter cells resulted in an increased
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uptake ofboth glucose and vitamin C, thus suggesting a role for this ligand in
spermatozoal physiology.
The lack ofexpression of the GM-CSF receptor in the marmoset may simply reflect
that this receptor is not present within these testes. However, given the previous
studies discussed above, and the lack of expression in marmoset thymus as a positive
control, it seems more likely that there was a problem with the primary antibody used,
and that further investigation using alternative antibodies is required before firm
conclusions are drawn.
5,4,7 Activin
Activins, along with inhibins, are members of the transforming growth factor-P
family, and are involved in the regulation ofFSH secretion (de Kretser etal, 2001).
However, it has also been suggested that these factors may have a local role within the
testis (Mather etal, 1997). Activin has been shown to stimulate spermatogonial
proliferation in vitro, in co-cultures of rat germ cells with Sertoli cells (Mather et al,
1990). In addition, activin has been shown to regulate gonocyte and Sertoli cell
proliferation in the postnatal rat testis (Boitani et al, 1995; Meehan et al, 2000).
Activins signal via the type II receptor serine kinases, ActRIIA or ActRIIB
(Massague, 1998). These receptors are expressed by Sertoli cells, spermatocytes and
round spermatids in the rat (de Winter et al, 1992). Expression of the ActRIIA
receptor has also been detected in gonocytes and interstitial cells of the human foetal
testis (Anderson et al, 2002).
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Within the prepubertal marmoset testis, a high proportion ofgerm cells have been
shown to express the ActRIIA receptor, a pattern that appeared unaffected by prior
treatment with a GnRH antagonist. The presence of this receptor may support a
paracrine role of activin within marmoset testis. However, the high level of
expression throughout many stages ofgerm cell development suggests activin is
unlikely to become a realistic target to suppress spermatogonial proliferation, and thus
protect fertility in boys treated for cancer.
This part of the study has identified a number ofgrowth factor receptors within the
prepubertal marmoset testis. These receptors demonstrate particular patterns of
expression, and this information will contribute to our understanding of the role these




Results- Stem Cell Markers
6.1 Introduction
It is hoped that the identification of growth factors that may act to regulate
spermatogonial proliferation prepubertally, as discussed in chapter 5, will lead to the
development of strategies to protect fertility in boys treated for cancer. However, as
survival of stem spermatogonia is essential for future fertility, this study also
investigated the immunoexpression of putative stem cell markers within the testis,
using this marmoset model. Stem spermatogonia are pluripotent germ cells capable
ofboth self-renewal and differentiation into other germ cell types. The identification
of stem spermatogonia would subsequently allow analysis of their relationship with
some of the growth factor receptors identified previously.
6.2 Methods
To identify stem spermatogonia within the marmoset testis, the immunoexpression of
markers reported to be unique to such cells was examined. Should it be possible to
reliably identify stem spermatogonia, the intention was to co-localise these cells, both
with markers of cell proliferation and the growth factor receptors discussed in chapter
5.
6.2,1 Animals
Sections of testis taken from marmosets killed at various time points, from the




Potential stem cell markers were selected on the basis of rodent models that have
previously investigated this cell population. C-kit is the trans-membrane receptor for
Stem Cell Factor (SCF) and is expressed in neonatal gonocytes in the rat (Orth et al,
1996). Oct-4 is a transcription factor expressed in totipotent embryonic stem and
germ cells in the mouse (Pesce and Scholer, 2001), and has been used for the
immunohistochemical detection of pluripotent cells in human germ cell tumours
(Looijenga et al, 2003). GFR-al, the receptor for GDNF, is expressed in murine
spermatogonia up to the A aligned stage (Meng et al, 2000).
6.2.3 Immunohistochemistrv
The immunohistochemical methods used for detecting the expression of these markers
are detailed in chapter 3. As with previous antibodies studied, each one required trials
under differing conditions to establish the optimal method of detection.
Co-localisation studies were initially performed using immunofluorescence.
However, immunopositive cells were difficult to identify with this method due to their
small number, together with problems ofbackground staining. Therefore, double
staining was also performed using conventional immunohistochemistry. Whilst one
antibody was visualised with DAB, the second antibody was visualised with Fast
Blue, as detailed in section 3.5.
6.3 Results
C-kit was localized to the peri-membranous region ofgerm cells within the neonatal
period (Fig 6. la). However, expression within the prepubertal age group was not
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Figure 6.1 Immunoexpression ofC-kit within (a) 1-day-old neonatal marmoset
testis (b) 35-week-old marmoset testis fc) Adult marmoset testis
(b) Immunoexpression ofC-kit
in testis from a 35-week-old
control animal. No expression
of this antigen is observed at
this age (20x magnification).
(a) Immunoexpression ofC-kit
in testis from a 1 day old
control animal. Peri-
membranous expression of this
antigen is observed in a
ofgerm cells at this age
(arrowed) (40x magnification).
(c) Immunoexpression ofC-kit . ,.f*
in testis from an adult control •*;" •, A
animal. Occasional germ cells ' V.-' ^ - ,6 » * »,7 • c • 1 »
are immunopositive for this , j ^ *J;' -> *
antigen (arrowed), although » . ( V' ** . ^ ' '
some non-specific staining
exists (indicated by A
arrowhead), making definitive "> ° -i'■ -
interpretation difficult (20x -f, \
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observed (Fig 6. lb). Limited expression within germ cells was noted in adulthood,
although apparent non-specific staining affected interpretation at this age (Fig 6.1c).
Expression of Oct-4 within germ cell nuclei was also prominent in the neonatal
period, but staining in older ages was rather non-specific, in that large numbers of
both germ cells and Sertoli cells appeared labelled (Fig 6.2).
As the growth factor receptors previously identified are prominent during the
prepubertal phase of testicular development, the aim was to identify a stem cell
marker that persisted into this period. GFR-al was expressed in occasional germ
cells throughout all ages studied, in a pattern consistent with stem cell labelling (Fig
6.3). In younger animals, positive cells were noted to be located both basally and in
the centre of the tubule away from the basement membrane, whereas from around 35
weeks onward germ cells expressing this antigen were exclusively basal.
To ascertain whether those germ cells expressing GFR-al were actively proliferating,
colocalization of this receptor was attempted with both PCNA and Ki67.
Immunofluorescent techniques to study GFR-al (Fig 6.4) were problematic, as
discussed above. Double staining using Fast Blue for detection of the proliferation
marker was therefore also used, as shown in Figure 6.5. These studies showed that
neither proliferation marker was expressed in the GFR-al positive cells, suggesting
that these cells were in a non-proliferative phase. However, fewer Ki67 positive cells
were noted throughout the sections than would be expected from previous studies
using DAB to visualise this marker, raising questions regarding the sensitivity ofFast
Blue detection.
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Figure 6.2 Immunoexpression of Oct-4 within (a) 1-dav-old neonatal marmoset
testis (b) 35-week-old marmoset testis fc) Adult marmoset testis
(a) Immunoexpression ofOct-4
in testis from a 1 day old
control animal. Numerous
germ cells appear to express
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(b) Immunoexpression ofOct-4
in testis from a 35 week old
control animal. Although a
proportion ofgerm cells appear
more intensely stained
(arrowed), numerous other
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(c) Immunoexpression ofOct-4
in testis from an adult control
animal. Although occasional
germ cells appear more
intensely stained (arrowed), as
at 35 weeks of age non-specific
staining exists, both in the




Figure 6.3 Immunoexpression ofGFR-al within fa) 2-dav-old neonatal
marmoset testis (b) 35-week-oId marmoset testis (c) Adult marmoset testis
(a) Immunoexpression ofGFR-
al in testis from a 2 day old
control animal. Occasional
germ cells express this receptor
at this age (such as the one
arrowed) (40x magnification).
(b) Immunoexpression ofGFR-
al in testis from a 35 week old
control animal. Occasional
germ cells express this receptor
at this age (such as the one
arrowed) (40x magnification).
(c) Immunoexpression ofGFR- 4 ^ > •
a 1 in testis from an adult • v'\. •* ■* & ~
control animal. Occasional & ° ' «
fs&'fc, ■ i 1 >-• * ■■ 'jj y i t, «, -A
germ cells express this receptor . ? r
at this age (such as those -
arrowed). Non-specific
staining ofelongate spermatid v * s)
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Figure 6.4 Localisation of the proliferation marker PCNA (green) with the GFR-
al receptor (red) in the marmoset testis using confocai microscopy
(a) prepubertal (b) adult
(blue staining represents counterstain with propidium iodide)
(a) Immunoexpression of
PCNA (green) and the GFR-al
receptor (red) in testis from an
18-24 week old control animal,
using confocai microscopy.
PCNA is localised to the
nucleus ofproliferating cells
(indicated by arrowheads). The
GFR-al receptor is expressed
in the cytoplasm of occasional
germ cells (solid arrow). There
is no evidence of co-
localisation of these antigens,
in that no cell expresses both





PCNA (green) and the GFR-al
receptor (red) in testis from an
adult control animal, using
confocai microscopy. PCNA is
localised to the nucleus of
proliferating cells (indicated by
arrowheads). The GFR-al
receptor is expressed in the
cytoplasm of occasional germ
cells (solid arrow). There is no
evidence of co-localisation of
these antigens, in that no cell
expresses both antigens at the





Figure 6.5 Localisation of the proliferation marker Ki67 (Fast Blue) with the
GFR-al receptor (DAB) in the marmoset testis at 35 weeks of age using double
staining techniques
Immunoexpression ofKi67
together with the GFR-al
receptor in testis from a 35
week old control animal. Ki67
positive cells are stained with
Fast Blue (indicated by
arrowheads) whereas cells
expressing the GFR-al
receptor are stained with DAB
(indicated by solid arrows).
There is no evidence of co-
localisation of these antigens,
in that no cell expresses both
antigens at the same time,
although fewer cells are
immunopositive for Ki67 than
expected from earlier studies,
suggesting a lack of sensitivity
with the detection process used
for this antigen here.
149
6.4 Discussion
Within this part of the study, potential markers of stem cells in the marmoset testis
were investigated, in order to ascertain their relationship with the growth factor
receptors previously identified. Stem spermatogonia are capable of both
differentiation into cells committed to more mature spermatogonia (ultimately
resulting in spermatocytes and spermatozoa), and to self-renewal, in order to maintain
the stem cell population. Studying this vital cell type is problematic, due to the small
numbers of stem cells present within the testis, and the difficulty in identifying these
cells based on morphological characteristics.
C-kit is the trans-membrane tyrosine kinase receptor for Stem Cell Factor (SCF) and
is expressed in neonatal gonocytes in the rat (Orth et al, 1996). During
embryogenesis, SCF binding is thought to play a role in the migration and
proliferation of primordial germ cells (Orth et al, 1997). Based on rodent studies,
SCF also plays a role in adult spermatogenesis, enhancing germ cell survival via a
reduction in apoptosis (Yan et al, 2000). Sertoli cells produce SCF and the c-kit
receptor is expressed on spermatogonia from differentiating type A spermatogonia
through to pachytene spermatocytes (Vincent et al, 1998). However, expression of
this receptor is not present on undifferentiated A spermatogonia.
Using the marmoset model, expression of the c-kit receptor has been demonstrated
both on the membrane of neonatal germ cells and within the adult testis, in keeping
with previous reports in the rat. However, no evidence of expression was found in the
prepubertal testis.
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Oct-4 is a transcription factor involved in regulation of pluripotency during normal
development, and is detectable in embryonic stem and germ cells in the mouse (Pesce
and Scholer, 2001). Immunohistochemical detection of this protein in human germ
cell tumours suggests that Oct-4 represents a marker of pluripotent cells within the
gonads as well as within germ cell tumours (Looijenga et al, 2003). It therefore
represents a potentially useful avenue of investigation via which to study stem cells
within the testis.
Using the marmoset model, immunoexpression ofOct-4 was detected in numerous
germ cell nuclei during the neonatal period, although this finding was not consistent
in all animals studied at this age. In addition, the pattern of expression of this protein
during later stages of testicular development was difficult to elucidate because of the
apparent poor specificity of staining observed. This problem persisted despite using
alternative primary antibodies and attempts to optimise the immunohistochemical
technique. Further investigation using Oct-4 as a stem cell marker was therefore not
pursued, as reliable conclusions would be difficult to draw, particularly in the
prepubertal age group.
As discussed previously, spermatogonia in the mouse are thought to express GFR-al
up until the A-aligned stage (Meng et al, 2000). It is hypothesised that GDNF,
produced by Sertoli cells and acting via the GFR-al receptor, promotes stem cell
renewal and consequently acts to regulate the number of spermatogonial stem cells.
The immunoexpression ofGFR-al in the marmoset is certainly consistent with the
pattern expected for a marker associated with germ cells during the early stages of
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spermatogenesis. Within the neonatal period a number ofgerm cells expressed this
receptor. During the prepubertal phase of testicular development the GFR-al
positive germ cells represent a very small proportion of the total cells present. In
addition, the position of these cells within the seminiferous tubule undergoes a
transition at around 18 to 24 weeks of age, from predominantly central, away from the
basement membrane, to an exclusively basal location. In sections from postpubertal
and adult animals, positive cells are noted on the basement membrane of occasional
tubules.
Stem cells, by their nature, are very infrequent within the testis. It has been estimated
that 104 germ cells isolated from adult rodent testes contain as few as 2 stem cells
(Ogawa et al, 1997). The frequency ofGFR-al positive germ cells observed in the
marmoset is in keeping with these representing stem cells. However, attempts to co-
localize these cells with markers of proliferation suggest that germ cells expressing
the GFR-al receptor are not actively proliferating. This does not preclude these cells
from being stem cells, as not all will be proliferating at any given time. In addition,
the small number ofGFR-al positive cells present, and concerns regarding the
sensitivity ofKi67 detection with Fast Blue, will also have impaired the ability to
demonstrate simultaneous expression ofGFR-al with a proliferation marker.
However, distinct conclusions regarding the window ofGFR-al expression and its
functional significance in the marmoset are difficult to draw. In view of these
uncertainties, further studies of this marker with the growth factor receptors
previously identified were not performed.
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At present the investigation of stem cells in many tissues, including the testis, is
generating considerable interest within the scientific community. It is hoped that the
rapidly expanding literature on this cell type, particularly within rodent models, will
contribute to further studies of stem spermatogonia within the marmoset. This may
include further investigation of the GFR-al receptor, along with novel markers to





This study had two primary aims; firstly to investigate the hypothesis that prepubertal
germ cell proliferation in the primate is gonadotrophin independent, and secondly, if
this were to be confirmed, to investigate what factors do regulate their proliferation at
this age. This information may subsequently lead to the development of strategies to
protect fertility in prepubertal boys treated for cancer.
Firstly, as discussed previously, we can conclude that spermatogonial proliferation in
the prepubertal marmoset is gonadotrophin independent. This explains, at least in
part, the failure of gonadal protection strategies in both primates and humans based on
suppression of the hypothalamic-pituitary-gonadal axis. The failure of these studies,
despite the success observed in similar investigations using rats, also highlights the
difficulty in extrapolating data from rodent models studying spermatogenesis to
investigations involving primates. Significant differences exist between these species
(Weinbauer and Nieschlag, 1989), particularly during the prepubertal phase of
testicular development, and thus such studies must be interpreted in the appropriate
context.
Secondly, we have identified a number ofgrowth factors whose receptors are present
on germ cells in the primate testis prior to puberty. Of the growth factor receptors
studied here, the EGF receptor and the GFR-a2 appear particularly prominent on a
significant number ofgerm cells during the prepubertal period. However, the
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limitations of the study and the technical difficulties encountered cannot exclude roles
in germ cell regulation for the other growth factors investigated. In addition, those
selected for study here do not represent an exhaustive list of those potentially
involved, and indeed, additional and novel growth factors may be implicated in the
future as having a role within the prepubertal primate testis.
Although these receptors have been identified on germ cells, the role their
corresponding ligands may play in spermatogenesis is more difficult to ascertain.
Because germ cells expressing either the EGF receptor or GFR-a2 are not undergoing
active proliferation, it is speculated that the corresponding growth factors, EGF and
neurturin, regulate germ cell proliferation by inhibiting this process. These growth
factors may inhibit intrinsic germ cell proliferation, or alternatively interfere with
pathways that stimulate proliferative activity. This theory would appear to contradict
the consensus view on the role ofgrowth factors, but as discussed previously, there is
some evidence for an inhibitory role in rodent models, at least with regards to EGF.
Confirming the precise roles these factors may have in spermatogenesis in the primate
is problematic. Unlike studies involving rodents, where gene knockout models have
contributed much to the literature, such studies are not possible, either practically or
ethically, in primates. In vitro studies using cell lines in culture can provide useful
information, but extrapolation to in vivo systems reduces the validity of the results
obtained.
EGF and neurturin are not, however, unique to the primate. These factors have been
identified in rodent models, and despite interspecies differences, their role in
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spermatogenesis is likely to be similar. To date, confocal studies using these factors
with markers ofproliferation have not been previously reported, either in primates or
rodent models. However, it would appear that these ligands perhaps have a more
prominent role in the regulation ofgerm cell proliferation in primates, at least during
the prepubertal period.
This prominence may simply be due to the more protracted prepubertal phase in
primates as compared to rodents. Whilst this period lasts up until around 45 weeks of
age in the marmoset and 12 years in humans, puberty commences within 15-20 days
in the rat, and even sooner in the mouse. Thus although these growth factors may
have an important role prior to puberty in rodents, they are unlikely to make as
significant a contribution as in primates. In addition, because of its relatively short
time period, investigation of the prepubertal rodent is more limited than in primate
models. Following puberty, both FSH and testosterone become more dominant in the
regulation of spermatogenesis (Sharpe, 1994). However, these growth factors may
still have a role in the regulation of spermatogonial proliferation in adulthood, and
indeed the present study provides no evidence that the regulatory processes in the
postpubertal testis are different to those before puberty.
The significance of these growth factors in primates may also relate to their
evolutionary development. Spermatogenesis in the rodent is a highly efficient and
very organised process. This is in complete contrast to the inefficiency and poor
organisation found in testes from a number of primates. It is possible that 'higher'
mammals have lost this efficiency because they do not need to produce large numbers
ofoffspring in order to propagate their species. Indeed, fewer offspring may actually
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improve overall survival because of the more complex developmental requirements of
younger primates. Rodents, on the other hand, must produce large numbers of
offspring to continue the gene line. Therefore, one may speculate that
spermatogenesis in primates is perhaps regulated by more 'primitive' mechanisms,
such as the growth factors identified in this study.
7.2 Limitations of Immunohistochemistrv
Analyses of the immunoexpression of the receptors and their ligands discussed
highlight a number of the limitations of immunohistochemistry. Detection of proteins
via immunohistochemical methods is reliant on both the specificity of the primary
antibody and the sensitivity of the method of detection. Both these steps in the
procedure can be validated by the use of positive controls, using tissue that is known
to have positive expression of the antigen under investigation. However, many
primary antibodies used are species specific and therefore require appropriate tissue
from the same species to be obtained, which can be problematic.
However, with the exception of investigation of the GM-CSF receptor, the major
problem encountered in this immunohistochemical study was not lack of detection,
but of significant background staining in the sections studied. In this circumstance a
negative control is essential, in which primary antibody is omitted from one section.
This ascertains the contribution of the secondary antibody to the staining pattern
observed. Within the marmoset tissue studied here, these controls were negative,
suggesting that the secondary antibody was not the source of background staining but
that the primary antibody was not sufficiently specific. The use of alternative primary
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antibodies, along with various techniques to optimise immunohistochemical detection,
can be beneficial, but the interpretation of certain antigens studied here is limited.
The problem ofbackground staining is compounded by the use of
immunofluorescence. Tyramide enhancement is a very sensitive detection system,
but the primary antibodies used are the same as for conventional
immunohistochemistry, and therefore have the same specificity. Consequently,
significant background can impair the analysis and interpretation of these studies.
Despite these limitations, immunohistochemistry remains the only viable approach to
investigating the presence of proteins in a subset of cells within a multicellular tissue.
In addition, other scientific techniques that are applicable to rodent models are not
possible in primate research, as discussed previously. As such, these studies
contribute significantly to our current understanding of the marmoset testis, and will
help direct future investigation of the regulation of germ cell proliferation in this
species.
7.3 Future Studies
Future studies must initially be directed towards confirming the precise roles the
factors identified here have within the prepubertal primate testis, and more
specifically investigating the hypothesis that EGF and neurturin act in a paracrine
manner to inhibit spermatogonia! proliferation. The use of rodent models, particularly
prepubertal animals, will certainly contribute to this investigation. However, the
marmoset is the most appropriate animal model in which to take these studies
forward.
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Because gene knockout models, in vitro studies and other potentially useful
techniques such as RNA interference (RNAi), which can be used to 'silence' certain
genes, are not possible in primate species, alternative modes of investigation are
required. This may involve in vivo studies, with administration of either the growth
factor itself or an antagonist into the animal model and subsequent assessment of the
proliferation rate ofgerm cells. Administration could either be systemic or indeed
unilateral via the intratesticular route, and the use of co-twins will be invaluable for
analysis of the effect of any intervention. These studies will then assist in the design
of protective strategies to protect the testis from cytotoxic damage. In order for this to
be achieved the proliferation rate of spermatogonia, and particularly stem cells, must
be reduced, in order to reduce their susceptibility to cytotoxic agents. IfEGF and
neurturin work in an inhibitory manner then supplementation of these growth factors
may achieve this result. However, if these growth factors are only inhibitory within a
specific window of concentration, beyond which stimulation of proliferation occurs,
as has been suggested for EGF, then therapeutic intervention may be more difficult to
realise.
Should these studies prove that manipulation of these growth factors could protect the
prepubertal primate testis from cytotoxic damage, two further issues need to be
addressed before clinical application of this type of procedure.
Firstly, the relevance of these growth factors in the human testis must be established.
Although the marmoset is an excellent animal model in which to study
spermatogenesis, and certainly more representative than rodent models, differences
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may exist in the human that are important to identify. Studies are currently underway
on human testicular tissue, investigating the immunoexpression of the growth factor
receptors identified in the marmoset. However, problems with the quality and
variability of the tissue affect the interpretation of such results. In addition, obtaining
human testicular tissue for research purposes presents particular ethical difficulties.
Secondly, growth factors have numerous essential physiological roles outwith the
testis. Thus any manipulation of these factors must not cause any unacceptable
adverse effects. This may be particularly important both during childhood, when
normal growth and development are at a critical stage, and in patients with cancer,
due to the possibility ofgrowth factors acting on malignant cells.
Transgenic mice with overexpression ofEGF exhibit intrauterine growth retardation,
with birth weights half that of normal littermates (Wong et al, 2000). Administration
ofEGF to newborn mice also results in growth retardation and impairs the appearance
of several neurobehavioral signs of maturation (Calamandrei and Alleva, 1989).
GDNF and its related ligands are involved in neuronal survival and renal
development, which may potentially be affected by manipulation of these factors. In
addition, mutations of the RET signalling system cause several human diseases,
including papillary thyroid carcinoma, multiple endocrine neoplasia types 2A and 2B,
and Hirschsprung's disease (Takahashi, 2001).
The expression of the EGF receptor has been demonstrated in a variety of human
tumours, particularly those seen in the adult population such as breast cancer
(Normanno et al, 2003). Within these tissues, EGF may play a role in regulating the
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proliferation and survival ofmalignant cells. Indeed, anti-EGF receptor antibodies
and EGF receptor tyrosine kinase inhibitors have been developed as novel strategies
in the treatment of these tumours (Baselga, 2001). Transgenic mice with
overexpression ofGDNF develop malignant testicular tumours, which mimic
seminomas (Meng et al, 2001b).
Manipulation of either of these growth factors therefore has the theoretical potential to
interfere with a child's normal growth and development, or worsen their malignant
disease. These adverse effects are clearly unacceptable, and as such any intervention
to protect fertility in this manner must be of proven safety before clinical application,
both in the short and long term. Local treatment with intratesticular administration is
likely to be less problematic than systemic administration, but damage to the testes
must be minimised, and not outweigh any potential benefits.
A further issue that would need to be addressed, should fertility protection in this
manner become feasible, is the time required to achieve inhibition of spermatogonial
proliferation prior to commencing cytotoxic treatment. Suppression of the
hypothalamic-pituitary-gonadal axis in rodent models requires several weeks of
hormonal intervention before the gonadotoxic insult (Kurdoglu et al, 1994;
Kangasniemi et al, 1995). This delay is unsatisfactory for the majority of cancer
patients, who generally must start treatment soon after diagnosis. It is hoped that
further investigation of these growth factors in the prepubertal testis will indicate the
likely time period necessary for adequate testicular suppression.
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7.4 Ethical and Legal Issues
Manipulation of factors that regulate spermatogonia! proliferation in order to improve
future spermatogenesis, along with other techniques of fertility preservation such as
harvesting gonadal tissue for future use, are exciting prospects that provide hope for
children with cancer. Although there are still many scientific and technical issues to
resolve, this technology also raises a number of important ethical and legal issues,
which must be addressed before these procedures are utilised in a clinical setting.
Of prime importance, when considering options for future fertility following
childhood cancer treatment, must be that any decision is taken in the child's best
interests. Thus the advantages of any intervention, or of an active decision not to
intervene, must outweigh any disadvantages, both in the short and long term.
Attempts to preserve fertility must not raise unrealistic expectations, and must not
have undue adverse effects in either the patient or any subsequent offspring.
Comparing potential benefits with long-term risks is particularly problematic in this
situation. The effectiveness of therapeutic intervention is still unknown at present,
and it will be many years until expertise has improved sufficiently to assess it
realistically. However, unless these techniques are considered and appropriate
methods offered now, the opportunity of fertility preservation will be missed.
Deleterious effects will also take many years to folly evaluate, particularly with
respect to future progeny. Thus fertility preservation must be considered in the
context of clinical benefit within the management of childhood cancer, and also in the
context of ongoing research. Valid consent to perform these procedures is therefore
both a legal and ethical requirement.
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For consent to be valid it must be informed, obtained voluntarily and given by a
competent person. Legal competence to consent requires that the individual giving it
is able to understand the information given, believes it applies to them, retains it, and
uses it to make an informed choice. In view of the complexity of the issues
surrounding fertility preservation, the anxieties of both patients and their families at
the time of diagnosis, and the limited time for discussion due to the urgency of
commencing treatment, the validity of such consent may be impaired.
The issue of valid consent is further complicated by the age of the patient involved
and their degree ofunderstanding of the issues being discussed. Young persons over
the age of 16 years in Scotland, and 18 years in England and Wales may consent to
treatment under the Family Law Reform Act (1969). Otherwise consent is obtained
by proxy, from a parent or legal guardian. Younger children may give valid consent
if they demonstrate sufficient understanding and intelligence to enable them to make
an informed decision, so called "Gillick competence" (Gillick v West Norfolk and
Wisbech Area Authority, 1985). However, with respect to the storage and future use
of gametes, consent by proxy is specifically excluded by the Human Fertilisation and
Embryology Act (1990). Thus parents, or legal guardians, cannot give consent on
behalfof the child. Immature germ cells, however, are not within the HFEA
definition of a gamete as they are unable to take part in fertilisation. Therefore these
cells could be harvested with parental consent, if the procedure was in the child's best
interests. If this immature material were subsequently matured to produce gametes
this tissue would then fall under the jurisdiction of the HFEA.
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Consent in situations such as this should be viewed as a dynamic, continual process
that is adapted as new information becomes available. Indeed, many of the
difficulties discussed above may be alleviated by obtaining consent in different stages
(Grundy et al, 2001). The first stage of consent would be for the harvest and storage
of the gonadal tissue. The second stage, at a later date, would involve consent for the
use of stored germ cell material for both fertilisation and research. In addition it is
important to consider what should happen to stored gonadal tissue in the event of the
child's death. Whilst some would advocate destruction of the tissue in this situation,
others have suggested allowing the parents to consent for the tissue to be used for
research purposes (Wallace and Walker, 2001).
These issues must be addressed in order that new techniques are adequately regulated.
Following extensive, collaborative discussion within a multidisciplinary setting, a
number of recommendations have been suggested (Wallace and Walker, 2001; British
Fertility Society, 2003). These include ongoing, structured research with
centralization of data and rapid dissemination of results, a rigorous review of
procedures and development of the process of obtaining informed consent. This will




Infertility can be a major long-term side effect following treatment for childhood
cancer, and will become increasingly important as greater numbers of children survive
into adulthood. It is therefore imperative to consider ways of protecting or restoring
fertility at an early stage.
At present there is nothing to offer the prepubertal boy at risk of infertility. Protection
of fertility during gonadotoxic therapy by inducing testicular quiescence is a
potentially useful and acceptable mode of intervention for these patients. Although
there are numerous issues to be addressed before these techniques become reality, the
identification of factors that regulate spermatogonia! proliferation in the prepubertal
testis contributes both to our understanding of testicular physiology, and to devising
such intervention in this patient group. Further studies into this area may therefore
offer genuine hope for childhood cancer survivors at risk of infertility in the future.
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Appendix A- Cell quantification data for Chapter 4


















































Appendix B Quantification ofGFR-«2 immuno-positive cells (Figure 5.3)







i Control 4.533982 5.500566 0.824
Treated 6.853556 6.770205 1.012
ii Control 4.329006 10.18262 0.425
Treated 4.787974 4.215133 1.136
iii Control 6.349825 6.935125 0.916
Treated 2.985234 5.854137 0.510
iv Control 4.537608 3.99696 1.135
Treated 3.892298 6.217289 0.626
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